<SEC-DOCUMENT>0001193125-18-268294.txt : 20180906
<SEC-HEADER>0001193125-18-268294.hdr.sgml : 20180906
<ACCEPTANCE-DATETIME>20180906170058
ACCESSION NUMBER:		0001193125-18-268294
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20180906
DATE AS OF CHANGE:		20180906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-223221
		FILM NUMBER:		181058148

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d617367d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No. 333-223221 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of Securities<BR>To Be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount To Be<BR>Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed Maximum<BR>Offering Price<BR>Per Unit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed Maximum<BR>Aggregate Offering<BR>Price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee(1)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Floating Rate Notes due 2023</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$300,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">100.000%</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$300,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$37,350.00</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.000% Notes due 2021</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,000,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">99.865%</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$998,650,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$124,331.93</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.200% Notes due 2023</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,000,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">99.797%</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$997,970,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$124,247.27</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.600% Notes due 2028</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,000,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">99.841%</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$998,410,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$124,302.05</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.100% Notes due 2038</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$700,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">99.809%</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$698,663,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$86,983.54</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.200% Notes due 2048</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,000,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">99.762%</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$997,620,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$124,203.69</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated in accordance with Rule 457(r) of the Securities Act of 1933, as amended. The total registration fee
due for this offering is $621,418.50. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>(To Prospectus dated February&nbsp;26, 2018) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g617367g24t53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Pfizer Inc. </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>$300,000,000 FLOATING RATE NOTES DUE 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>$1,000,000,000&nbsp;&nbsp;&nbsp;&nbsp;3.000% NOTES DUE 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>$1,000,000,000&nbsp;&nbsp;&nbsp;&nbsp;3.200% NOTES DUE 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>$1,000,000,000&nbsp;&nbsp;&nbsp;&nbsp;3.600% NOTES DUE 2028 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>$700,000,000&nbsp;&nbsp;&nbsp;&nbsp;4.100% NOTES DUE 2038 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>$1,000,000,000&nbsp;&nbsp;&nbsp;&nbsp;4.200% NOTES DUE 2048 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The floating rate notes (the &#147;floating rate notes&#148;) will mature on&nbsp;September&nbsp;15, 2023, the 2021 notes (the &#147;2021 notes&#148;) will
mature on&nbsp;September&nbsp;15, 2021, the 2023 notes (the &#147;2023 notes&#148;) will mature on&nbsp;September&nbsp;15, 2023, the 2028 notes (the &#147;2028 notes&#148;) will mature on&nbsp;September&nbsp;15, 2028, the 2038 notes (the &#147;2038
notes&#148;) will mature on&nbsp;September&nbsp;15, 2038 and the 2048 notes (the &#147;2048 notes&#148;) will mature on&nbsp;September&nbsp;15, 2048. We refer to the 2021 notes, the 2023 notes, the 2028 notes, the 2038 notes and the 2048 notes
collectively as the &#147;fixed rate notes,&#148; and the fixed rate notes and the floating rate notes collectively as the &#147;notes.&#148; The notes will be our unsecured and unsubordinated debt obligations and will not have the benefit of any
sinking fund. The notes will rank equally with all other unsecured and unsubordinated indebtedness of Pfizer from time to time outstanding. Interest on the floating rate notes will be payable quarterly in arrears on&nbsp;March&nbsp;15, June&nbsp;15,
September&nbsp;15 and December&nbsp;15 of each year, beginning on&nbsp;December&nbsp;15, 2018. Interest on the fixed rate notes will be payable semi-annually in arrears on&nbsp;March&nbsp;15 and September&nbsp;15&nbsp;of each year, beginning
on&nbsp;March&nbsp;15, 2019. The fixed rate notes of each series are redeemable in whole or in part at our option at the prices set forth in this prospectus supplement. We may not redeem the floating rate notes at our option prior to maturity. </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in the notes involves risks. See &#147;<A HREF="#supprom617367_3">Risk Factors</A>&#148; beginning on page
<FONT STYLE="white-space:nowrap">S-4</FONT> of this prospectus supplement and beginning on page 10 of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Public&nbsp;Offering</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Underwriting</B><br><B>Discount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Offering&nbsp;Proceeds&nbsp;to<BR>Pfizer,&nbsp;Before&nbsp;Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Per Floating Rate Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.000</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.350</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.650</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Floating Rate Notes Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300,000,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">298,950,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Per 2021 Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.865</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.615</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">2021 Notes Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">998,650,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">996,150,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Per 2023 Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.797</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.350</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.447</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">2023 Notes Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">997,970,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">994,470,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Per 2028 Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.841</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.450</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.391</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">2028 Notes Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">998,410,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">993,910,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Per 2038 Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.809</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.750</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.059</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">2038 Notes Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">698,663,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">693,413,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Per 2048 Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.762</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.750</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.012</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">2048 Notes Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">997,620,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">990,120,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Plus accrued interest from September&nbsp;7, 2018, if settlement occurs after that date. </P></TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Neither the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) nor any state securities commission has approved or disapproved of these securities
or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The underwriters expect to deliver the notes through the facilities of The Depository Trust Company (&#147;DTC&#148;) for the accounts of its direct
participants, including Clearstream Banking, <I>soci&eacute;t&eacute; anonyme</I> and Euroclear Bank S.A./N.V., as operator of the Euroclear System, against payment therefor in New York, New York on or about&nbsp;September&nbsp;7, 2018. </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><I>Joint Book-Running Managers </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:15pt">


<TR>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:15pt">
<TD VALIGN="top" NOWRAP><B>BofA&nbsp;Merrill&nbsp;Lynch</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Citigroup&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Credit Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Morgan&nbsp;Stanley</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13pt">


<TR>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top" NOWRAP><B>Barclays</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>HSBC</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><I>Senior Co-Managers </I></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"><B>Deutsche Bank Securities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Santander</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><I>Co-Managers </I></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Mizuho Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>RBC Capital Markets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Academy Securities</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Ramirez &amp; Co., Inc.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Siebert&nbsp;Cisneros&nbsp;Shank&nbsp;&amp;&nbsp;Co., L.L.C.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>The Williams Capital Group, L.P.</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;4, 2018 </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_1">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">iii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_4">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_6">DESCRIPTION OF NOTES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_7">U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_8">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom617367_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_2">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_5">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_8">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_9">DESCRIPTION OF OTHER SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_10">SELLING SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No person is authorized to give any information or to make any representations other than those contained or incorporated
by reference in this prospectus supplement or the accompanying prospectus and any free writing prospectus we may provide you in connection with this offering. We and the underwriters take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. This prospectus supplement and the accompanying prospectus are not an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction where it is unlawful.
Neither the delivery of this prospectus supplement or the accompanying prospectus, nor any sale of notes made under these documents, will, under any circumstances, create any implication that there has been no change in our affairs since the date of
this prospectus supplement, the accompanying prospectus or any free writing prospectus we may provide you in connection with this offering or that the information contained or incorporated by reference is correct as of any time subsequent to the
date of such information. You should assume that the information in this prospectus supplement and the accompanying prospectus, as well as the information incorporated by reference in this prospectus supplement and the accompanying prospectus, is
accurate only as of the date of the documents containing the information, unless the information specifically indicates that another date applies. Our business, financial condition, results of operations and prospects may have changed since those
dates. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first is this prospectus supplement, which describes the specific terms of this offering. The second part,
the accompanying prospectus, contains a description of our debt securities and gives more general information, some of which may not apply to this offering. This prospectus supplement also adds </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to, updates and changes information contained in the accompanying prospectus. If the description of the offering varies between this prospectus supplement and the accompanying prospectus, you
should rely on the information in this prospectus supplement. The accompanying prospectus is part of a registration statement that we filed with the SEC using a shelf registration statement. Under the shelf registration process, from time to time,
we may offer and sell securities in one or more offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">References in this prospectus supplement to &#147;Pfizer,&#148; the &#147;Company,&#148;
&#147;we,&#148; &#147;us&#148; and &#147;our&#148; are to Pfizer Inc. and its consolidated subsidiaries unless otherwise stated or the context so requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_1"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus, as well as the information incorporated by reference in this prospectus supplement and
the accompanying prospectus, may include forward-looking statements made within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and Section&nbsp;21E of the Securities Exchange Act of 1934,
as amended (the &#147;Exchange Act&#148;). Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as &#147;will,&#148; &#147;may,&#148;
&#147;could,&#148; &#147;likely,&#148; &#147;ongoing,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;project,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;assume,&#148; &#147;target,&#148;
&#147;forecast,&#148; &#147;guidance,&#148; &#147;goal,&#148; &#147;objective,&#148; &#147;aim&#148; and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, our anticipated
operating and financial performance, business plans and prospects, <FONT STYLE="white-space:nowrap">in-line</FONT> products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, performance,
timing of exclusivity and potential benefits of our products and product candidates,<I> </I>strategic reviews, capital allocation, business-development plans, the benefits expected from our plans to organize our commercial operations into three
businesses effective at the beginning of our 2019 fiscal year, our acquisitions and other business development activities, manufacturing and product supply<I> </I>and plans relating to share repurchases and dividends. In particular, these include
statements relating to future actions, business plans and prospects, our acquisitions and other business development activities, the disposition of the Hospira Infusion Systems net assets, prospective products or product approvals, future
performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, plans relating to share repurchases and dividends, government
regulation and financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A list and description of risks, uncertainties and other matters can be found in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017 and in our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended April&nbsp;1, 2018 and July&nbsp;1, 2018, in each case
including in the sections thereof captioned &#147;Forward-Looking Information and Factors That May Affect Future Results&#148; and &#147;Risk Factors,&#148; in our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and in this
prospectus supplement and accompanying prospectus, in each case including in the section thereof captioned &#147;Risk Factors.&#148; You should understand that it is not possible to predict or identify all such factors. Consequently, you should not
consider any such list to be a complete set of all potential risks or uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any forward-looking statement will be
realized, although we believe we have been prudent in our plans and assumptions. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties
materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements, and you
are cautioned not to put undue reliance on forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We undertake no obligation to publicly update forward-looking statements, whether
as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects in our Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> reports and our other filings with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary highlights information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. It does
not contain all of the information that you should consider before investing in the notes. You should carefully read this entire prospectus supplement, as well as the accompanying prospectus and the documents incorporated by reference that are
described under &#147;Where You Can Find More Information.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pfizer Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pfizer is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and
significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world&#146;s best-known consumer healthcare products. We work
across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access
to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products, and, to a much lesser extent, from alliance agreements, under which we <FONT STYLE="white-space:nowrap">co-promote</FONT> products
discovered or developed by other companies or us. The majority of our revenues come from the manufacture and sale of biopharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our <FONT STYLE="white-space:nowrap">in-line</FONT> products, as well as through various forms of business development, which can include
alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We regularly evaluate, engage in preliminary discussions concerning, and, where appropriate, execute on these
opportunities, although we cannot predict whether we will enter into any such transaction and, if so, the terms or financing needs in connection therewith. Pursuing these opportunities may require us to obtain additional equity or debt financing,
which could result in increased leverage and/or a downgrade of our credit ratings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;11, 2018, we announced that effective at the beginning of
our 2019 fiscal year, we will modify our structure to organize the company into three businesses: a science based Innovative Medicines business; an <FONT STYLE="white-space:nowrap">off-patent</FONT> branded and generic Established Medicines business
operating with substantial autonomy within Pfizer; and a Consumer Healthcare business. Our Established Medicines business will have distinct and fully-dedicated manufacturing, marketing, regulatory and with some exceptions, enabling functions which
will enhance its autonomy and position it to operate as a true standalone business within Pfizer. Our focus in the Established Medicines business is to stand up this business as a successful emerging-markets based business. The Consumer Healthcare
business has been operating independently, with dedicated manufacturing and regulatory capabilities and will operate with increased independence going forward. This new structure is designed to position each business to optimize its growth
potential, while providing us with future flexibility to access opportunities to maximize value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we continue to review strategic options
for our Consumer Healthcare business. We remain disciplined regarding our capital allocation, and at this time we have not received an acceptable offer for the sale of this business. We will continue our management of this strong business as we
explore other alternatives, which could include everything from a full or partial separation of the business to ultimately deciding to retain the business. We continue to expect that any decision regarding strategic alternatives for our Consumer
Healthcare business will be made during 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pfizer Inc. was incorporated under the laws of the State of Delaware on June&nbsp;2, 1942. Our principal
executive offices are located at 235 East 42nd Street, New York, NY 10017-5703 and our telephone number is (212) <FONT STYLE="white-space:nowrap">733-2323.</FONT> </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following is a brief summary of the terms and conditions of this offering. It does not contain all of the information that you need to consider in
making your investment decision. To understand all of the terms and conditions of the offering of the notes, you should carefully read this prospectus supplement, as well as the accompanying prospectus and the documents incorporated by reference.
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Issuer</B> </P></TD>
<TD>Pfizer Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Securities Offered</B> </P></TD>
<TD>$300,000,000 aggregate principal amount of floating rate notes due 2023; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$1,000,000,000 aggregate principal amount of&nbsp;3.000% notes due 2021; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$1,000,000,000 aggregate principal amount of&nbsp;3.200% notes due 2023; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$1,000,000,000 aggregate principal amount of&nbsp;3.600% notes due 2028; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$700,000,000 aggregate principal amount of&nbsp;4.100% notes due 2038; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$1,000,000,000 aggregate principal amount of&nbsp;4.200% notes due 2048. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Original Issue Date</B> </P></TD>
<TD>September&nbsp;7, 2018. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Maturity Date</B> </P></TD>
<TD>September&nbsp;15, 2023 for the floating rate notes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">September&nbsp;15, 2021 for the 2021 notes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">September&nbsp;15, 2023 for the 2023 notes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">September&nbsp;15, 2028 for the 2028 notes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">September&nbsp;15, 2038 for the 2038 notes; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">September&nbsp;15, 2048 for the 2048 notes. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Interest Rate</B> </P></TD>
<TD>Three-month LIBOR plus&nbsp;0.33% per annum for the floating rate notes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3.000% per annum for the 2021 notes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3.200% per annum for the 2023 notes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3.600% per annum for the 2028 notes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4.100% per annum for the 2038 notes; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4.200% per annum for the 2048 notes. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Interest Payment Dates</B> </P></TD>
<TD>Interest on the floating rate notes will accrue from and including&nbsp;September 7, 2018, and is payable quarterly in arrears on March 15, June 15, September 15, and December 15 of each year, beginning on&nbsp;December 15, 2018.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest on the fixed rate notes will accrue from and including&nbsp;September 7, 2018, and is payable on March 15&nbsp;and September 15&nbsp;of each year, beginning on&nbsp;March 15, 2019. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption</B> </P></TD>
<TD>We will have the right at our option to redeem the fixed rate notes of any series, in whole or in part, at any time or from time to time, at the redemption prices described in &#147;Description of Notes&#151;Optional Redemption of Fixed Rate
Notes; No Sinking Fund.&#148; We may not redeem the floating rate notes at our option prior to maturity. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Ranking</B> </P></TD>
<TD>The notes will be unsecured general obligations of Pfizer and will rank equally with all other unsecured and unsubordinated indebtedness of Pfizer from time to time outstanding. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Further Issues</B> </P></TD>
<TD>We may, without the consent of the holders of notes of any series, issue additional notes having the same ranking and the same interest rate, maturity and other terms as the notes of any series (except for the issue price and the public offering
price). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Denomination</B> </P></TD>
<TD>We will issue the notes in denominations of $2,000 and in integral multiples of $1,000 in excess of $2,000. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Trading</B> </P></TD>
<TD>The notes will not be listed on any national securities exchange or be quoted on any automated dealer quotation system. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Trustee</B> </P></TD>
<TD>The Bank of New York Mellon. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors</B> </P></TD>
<TD>You should consider carefully all the information set forth and incorporated by reference in this prospectus supplement and the accompanying prospectus and, in particular, you should evaluate the information set forth under the heading
&#147;Risk Factors&#148; in this prospectus supplement before investing in the notes. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Before purchasing the notes, you should consider carefully the information under the headings &#147;Risk Factors&#148; in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017 and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended April&nbsp;1, 2018 and July&nbsp;1, 2018 and the
following risk factors. You should also carefully consider the other information included in this prospectus supplement, the accompanying prospectus and other information incorporated by reference herein and therein. Each of the risks described in
these documents could materially and adversely affect our business, financial condition, results of operations and prospects, and could result in a partial or complete loss of your investment. See &#147;Where You Can Find More Information.&#148;
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The notes are unsecured and will be effectively junior to our secured indebtedness to the extent of the collateral therefor. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are our unsecured general obligations. Holders of our secured indebtedness, if any, will have claims that are prior to your claims as holders of the
notes, to the extent of the assets securing such indebtedness. Thus, in the event of a bankruptcy, liquidation, dissolution, reorganization or similar proceeding, our pledged assets would be available to satisfy obligations of our secured
indebtedness before any payment could be made on the notes. To the extent that such assets cannot satisfy in full our secured indebtedness, the holders of such indebtedness would have a claim for any shortfall that would rank equally in right of
payment with the notes. In any of the foregoing events, we cannot assure you that there will be sufficient assets to pay amounts due on the notes. As a result, holders of the notes may receive less, ratably, than holders of our secured indebtedness.
At July&nbsp;1, 2018, Pfizer Inc. had no secured indebtedness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Active trading markets may not develop for the notes and the notes may trade at a
discount from their initial offering price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are new issuances of securities for which no public trading markets currently exist.
Although the underwriters have informed us that they intend to make markets in the notes, they are not obligated to do so, and any such market-making activities may be discontinued at any time without notice. Accordingly, liquid markets for the
notes may not develop or be maintained. The notes will not be listed on any national securities exchange or be quoted on any automated dealer quotation system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, subsequent to their initial issuance, the notes may trade at a discount from their initial offering prices, depending upon prevailing interest
rates, the markets for similar notes, our performance and other factors. The markets for the notes may not be free from disruptions that may adversely affect the prices at which you may sell the notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of the notes will be structurally subordinated to our subsidiaries&#146; third-party indebtedness and obligations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are obligations of Pfizer Inc. exclusively and not of any of our subsidiaries. A significant portion of our operations is conducted through our
subsidiaries. Our subsidiaries are separate legal entities that have no obligation to pay any amounts due under the notes or to make any funds available therefor, whether by dividends, loans or other payments. Except to the extent we are a creditor
with recognized claims against our subsidiaries, all claims of third-party creditors (including trade creditors) and holders of preferred stock, if any, of our subsidiaries will have priority with respect to the assets of such subsidiaries over the
claims of our creditors, including holders of the notes. Consequently, the notes will be structurally subordinated to all existing and future liabilities of any of our subsidiaries and any subsidiaries that we may in the future acquire or establish.
As of July&nbsp;1, 2018, our wholly-owned subsidiaries had aggregate borrowings under lines of credit and outstanding debt securities of approximately $6.1&nbsp;billion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The amount of interest payable on the floating rate notes is set only once per quarter based on the
three-month LIBOR rate on the interest determination date, which rate may fluctuate substantially. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historically, the level of the three-month
LIBOR has experienced significant fluctuations. You should note that historical levels, fluctuations and trends of the three-month LIBOR rate are not necessarily indicative of future levels, fluctuations and/or trends. Any historical upward or
downward trend in the three-month LIBOR rate is not an indication that the three-month LIBOR rate is more or less likely to increase or decrease at any time during a floating rate interest period, and you should not take the historical levels of the
three-month LIBOR rate as an indication of its future performance. You should further note that although the actual three-month LIBOR rate on an interest payment date or at other times during an interest period may be higher than the three-month
LIBOR rate on the applicable interest determination date, you will not benefit from the three-month LIBOR rate at any time other than on the interest determination date for such interest period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Uncertainty relating to the LIBOR calculation method and the potential phasing out of LIBOR after 2021 may adversely affect the value of the floating
rate notes. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;27, 2017, the UK Financial Conduct Authority (&#147;FCA&#148;) announced that it will no longer persuade or compel banks
to submit rates for the calculation of the LIBOR rates after 2021 and that market participants should not rely on LIBOR being available after 2021 (the &#147;FCA Announcement&#148;). It is not possible to predict the effect of the FCA Announcement,
any changes in the methods pursuant to which the LIBOR rates are determined and any other reforms to LIBOR, including to the rules promulgated by the FCA in relation thereto, that will be enacted in the United Kingdom and elsewhere, which may
adversely affect the trading market for LIBOR-based securities, including the floating rate notes, result in the phasing out of LIBOR as a reference rate for securities, or both. In addition, any changes announced by the FCA (including the FCA
Announcement), ICE Benchmark Administration Limited as independent administrator of LIBOR or any other successor governance or oversight body, or future changes adopted by such body, in the method pursuant to which the LIBOR rates are determined may
result in a sudden or prolonged increase or decrease in the reported LIBOR rates. If that were to occur, the level of interest payments and the value of the floating rate notes may be materially affected. Further, uncertainty as to the extent and
manner in which the United Kingdom government&#146;s recommendations following its review of LIBOR in September 2012 will continue to be adopted and the timing of such changes may adversely affect the current trading market for LIBOR based
securities and the value of the floating rate notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the floating rate notes, if LIBOR were to be permanently discontinued, the
calculation agent will use an alternative reference rate that is consistent with accepted market practice at the time, as described in &#147;Description of Notes&#151;Interest&#151;Floating Rate Notes,&#148; which could result in an interest rate
that is different from what would have otherwise been calculated using LIBOR and could materially affect the value of the floating rate notes. Any such change in the calculation of the interest rate on the floating rate notes may result in U.S.
federal income tax or other tax consequences to holders or beneficial owners of the floating rate notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We regularly evaluate, engage in
preliminary discussions concerning, and, where appropriate, execute on growth opportunities, although we cannot predict whether we will enter into any such transaction and, if so, the terms or financing needs in connection therewith. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our
<FONT STYLE="white-space:nowrap">in-line</FONT> products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and
acquisitions. We regularly evaluate, engage in preliminary discussions concerning, and, where appropriate, execute on these opportunities, although we cannot predict whether we will enter into any such transaction and, if so, the terms or financing
needs in connection therewith. Pursuing these opportunities may require us to obtain additional equity or debt financing, and could result in increased leverage and/or a downgrade of our credit ratings. For example, we continue to review strategic
options for our Consumer Healthcare business and expect that any decision regarding strategic alternatives for our Consumer Healthcare business will be made during </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2018. In July 2018, we also announced the reorganization of the structure of our company into three businesses, which is designed to better position each business to optimize its growth potential
while providing us with future flexibility to access opportunities to maximize value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_4"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated ratio of earnings to fixed charges for each of the years ended December&nbsp;31, 2013 through 2017 and the six months ended July&nbsp;1, 2018
is set forth below. All financial information for the year ended December&nbsp;31, 2013 reflects the June&nbsp;24, 2013 disposition of Zoetis Inc. and its presentation as a discontinued operation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of computing the ratio of earnings to fixed charges, &#147;earnings&#148; consists of income from continuing operations before provision for
taxes on income and before income or loss from equity-method investments, plus fixed charges, distributed income of equity-method investments and amortization of capitalized interest, and less capitalized interest. &#147;Fixed charges&#148; consists
of interest expense (which includes amortization of debt premium, discount and other debt costs), preferred stock <FONT STYLE="white-space:nowrap">dividends,&nbsp;one-third&nbsp;of</FONT> rental expense, which we believe to be a conservative
estimate of an interest factor in our leases, which are not material, and capitalized interest. The ratio was calculated by dividing the sum of the earnings (as defined above) by the sum of the fixed charges (as defined above). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>July&nbsp;1, 2018</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratio of earnings to fixed charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to receive net proceeds from this offering of $4,967,013,000 (after deducting underwriting discounts, but before deducting expenses of the
offering). We intend to use the net proceeds for general corporate purposes, including to refinance, redeem or repurchase existing debt and to repay a portion of our outstanding commercial paper. As of August&nbsp;28, 2018, we had approximately
$3.8&nbsp;billion of commercial paper outstanding with a weighted average annual interest rate of 2.11% and a weighted average maturity of 29 days. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_6"></A>DESCRIPTION OF NOTES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Each series of notes is a series of debt securities described in the accompanying prospectus. Reference should be made to the accompanying prospectus for a
detailed summary of additional provisions of the notes and of the indenture to be dated on or about September&nbsp;7, 2018, between Pfizer and The Bank of New York Mellon, as trustee, which we refer to as the &#147;base indenture,&#148; as
supplemented by the first supplemental indenture to be dated as of September&nbsp;7, 2018, between Pfizer Inc. and The Bank of New York Mellon, as trustee, which we refer to as the &#147;first supplemental indenture.&#148; When we refer to the
&#147;indenture,&#148; we mean the base indenture as supplemented by the first supplemental indenture. The following description is a summary of selected portions of the base indenture and the first supplemental indenture. It does not restate the
base indenture or the first supplemental indenture, and those documents, not this description, define your rights as a holder of the notes. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>References in this section to &#147;Pfizer,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; are to Pfizer Inc., unless otherwise stated or the
context so requires. The provisions described in the accompanying prospectus under the heading &#147;Description of Debt Securities&#151;Defeasance&#148; will apply to the notes. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal, Maturity and Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The floating rate notes
will initially be limited to $300,000,000 aggregate principal amount, the 2021 notes will initially be limited to $1,000,000,000 aggregate principal amount, the 2023 notes will initially be limited to $1,000,000,000 aggregate principal amount, the
2028 notes will initially be limited to $1,000,000,000 aggregate principal amount, the 2038 notes will initially be limited to $700,000,000 aggregate principal amount and the 2048 notes will initially be limited to $1,000,000,000 aggregate principal
amount. The floating rate notes will mature on September&nbsp;15, 2023 (the &#147;Floating Rate Maturity Date&#148;), the 2021 notes will mature on September&nbsp;15, 2021, the 2023 notes will mature on September&nbsp;15, 2023, the 2028 notes will
mature on September&nbsp;15, 2028, the 2038 notes will mature on September&nbsp;15, 2038 and the 2048 notes will mature on September&nbsp;15, 2048. We will issue the notes in denominations of $2,000 and in integral multiples of $1,000 in excess of
$2,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The floating rate notes will bear interest at a floating rate equal to LIBOR plus 0.33% per annum, as described under
&#147;&#151;Interest&#151;Floating Rate Notes.&#148; Interest on the floating rate notes will accrue from and including September&nbsp;7, 2018, to, but excluding, the first interest payment date and then from and including the immediately preceding
interest payment date to which interest has been paid or duly provided for to, but excluding, the next interest payment date or maturity date, as the case may be. We refer to each of these periods as an &#147;interest period.&#148; The amount of
accrued interest that we will pay for any interest period can be calculated by multiplying the face amount of the floating rate notes then outstanding by an accrued interest factor. This accrued interest factor is computed by adding the interest
factor calculated for each day from September&nbsp;7, 2018, or from the last date we paid interest to you, to the date for which accrued interest is being calculated. The interest factor for each day is computed by dividing the interest rate
applicable to that day by 360. We will make interest payments on the floating rate notes quarterly in arrears on each March&nbsp;15, June&nbsp;15, September&nbsp;15 and December&nbsp;15, beginning on December&nbsp;15, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest on the 2021 notes will accrue at the annual rate of 3.000%, interest on the 2023 notes will accrue at the annual rate of 3.200%, interest on the 2028
notes will accrue at the annual rate of 3.600%, interest on the 2038 notes will accrue at the annual rate of 4.100% and interest on the 2048 notes will accrue at the annual rate of 4.200%. Interest on the fixed rate notes will accrue from and
including September&nbsp;7, 2018, and is payable on March&nbsp;15 and September&nbsp;15 of each year, beginning on March&nbsp;15, 2019. Interest on the fixed rate notes will be computed on the basis of a
<FONT STYLE="white-space:nowrap">360-day</FONT> year comprised of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will make each
interest payment to the holders of record of the fixed rate notes at the close of business on the March&nbsp;1 or September&nbsp;1 immediately preceding the relevant interest payment date. We will make each interest payment to the holders of record
of floating rate notes at the close of business on the March&nbsp;1, June&nbsp;1, September&nbsp;1 and December&nbsp;1 immediately preceding the relevant interest payment date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trustee, through its corporate trust office in the Borough of Manhattan, City of New York (in such
capacity, the &#147;paying agent&#148;) will act as our paying agent with respect to the notes. Payments of principal, interest and premium, if any, will be made by us through the paying agent to DTC as described under &#147;&#151;Book-Entry
System.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest&#151;Floating Rate Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
interest rate on the floating rate notes will be calculated by The Bank of New York Mellon, as calculation agent, and will be equal to LIBOR plus&nbsp;0.33%. The calculation agent will set the initial interest rate on September&nbsp;5, 2018 and
reset the interest rate on each interest payment date, each of which we refer to as an &#147;interest reset date.&#148; The second London business day preceding an interest reset date will be the &#147;interest determination date&#148; for that
interest reset date. The interest rate in effect on each day that is not an interest reset date will be the interest rate determined as of the interest determination date pertaining to the immediately preceding interest reset date. The interest rate
in effect on any day that is an interest reset date will be the interest rate determined as of the interest determination date pertaining to that interest reset date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;LIBOR&#148; will be determined by the calculation agent in accordance with the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) With respect to any interest determination date, LIBOR will be the rate for deposits in United States dollars having a
maturity of three months commencing on the first day of the applicable interest period that appears on either Reuters Page LIBOR01 or Bloomberg L.P. page BBAM as of 11:00 a.m., London time, on that interest determination date. If no rate appears on
Reuters Page LIBOR01 or Bloomberg L.P. page BBAM as of approximately 11:00 a.m., London time, on such interest determination date, LIBOR for that interest determination date will be determined in accordance with the provisions described in
(b)&nbsp;below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) With respect to an interest determination date on which no rate appears on Reuters Page LIBOR01 or
Bloomberg L.P. page BBAM, as specified in (a)&nbsp;above, the calculation agent will request the principal London offices of each of four major reference banks in the London interbank market, as selected by the calculation agent (after consultation
with us), to provide the calculation agent with its offered quotation for deposits in United States dollars for the period of three months, commencing on the first day of the applicable interest period, to prime banks in the London interbank market
at approximately 11:00 a.m., London time, on that interest determination date and in a principal amount that is representative for a single transaction in United States dollars in that market at that time. If at least two quotations are provided,
then LIBOR on that interest determination date will be the arithmetic mean of those quotations. If fewer than two quotations are provided, then LIBOR on the interest determination date will be the arithmetic mean of the rates quoted at approximately
11:00 a.m., in The City of New York, on the interest determination date by three major banks in The City of New York selected by the calculation agent (after consultation with us) for loans in United States dollars to leading European banks, having
a three-month maturity and in a principal amount that is representative for a single transaction in United States dollars in that market at that time. If, however, the banks selected by the calculation agent are not providing quotations in the
manner described by the previous sentence, LIBOR determined as of that interest determination date will be LIBOR in effect on that interest determination date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding clause (b)&nbsp;above, if we determine that three-month LIBOR has been permanently discontinued, or the
reference to three-month LIBOR becomes illegal, or most other debt obligations similar to the floating rate notes have converted away from three-month LIBOR to a new reference rate, the calculation agent will use, as directed by us, as a substitute
for three-month LIBOR and for each future interest determination date, the alternative reference rate (the &#147;Alternative Rate&#148;) selected by the central bank, reserve bank, monetary authority or any similar institution (including any
committee or working group thereof) that is consistent with accepted market practice. As part of such substitution, the calculation agent will, as directed by us, make such adjustments (&#147;Adjustments&#148;) to the Alternative Rate and the spread
thereon to account for the basis between three-month LIBOR and the Alternative Rate, as well as the business day convention, interest determination dates and related provisions and definitions, in each case
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
that are consistent with accepted market practice for the use of such Alternative Rate for debt obligations such as the floating rate notes. If we determine there is no clear market consensus as
to whether any rate has replaced LIBOR in customary market usage, we may appoint in our sole discretion an independent financial advisor (the &#147;IFA&#148;) to determine an appropriate Alternative Rate, and any Adjustments, and the decision of the
IFA will be binding on us, the calculation agent, the trustee and the holders. If, however, the calculation agent determines that three-month LIBOR has been discontinued, but for any reason an Alternative Rate has not been determined, three-month
LIBOR will be equal to such rate on the interest determination date when three-month LIBOR was last available on the Reuters LIBOR01 Page or Bloomberg L.P. page BBAM, as determined by the calculation agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Bloomberg L.P. page BBAM&#148; means the display designated as the Bloomberg L.P. page &#147;BBAM&#148; (or such other screen as may replace the
Bloomberg L.P. page &#147;BBAM&#148; on the service (or any successor service) as may be nominated by ICE Benchmark Administration for the purpose of displaying London interbank rates of major banks for U.S. dollar deposits). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Reuters Page LIBOR01&#148; means the display designated on page LIBOR01 by Reuters Group plc (or such other page as may replace the LIBOR01 page on that
service (or any successor service) or such other service as may be nominated by the British Bankers&#146; Association for the purpose of displaying London interbank offered rates for U.S. dollar deposits). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All percentages resulting from any calculation of the interest rate on the floating rate notes will be rounded to the nearest one hundred-thousandth of a
percentage point with five one millionths of a percentage point rounded upwards (e.g., 9.876545% (or .09876545) would be rounded to 9.87655% (or .0987655)), and all dollar amounts used in or resulting from such calculation on the floating rate notes
will be rounded to the nearest cent (with <FONT STYLE="white-space:nowrap">one-half</FONT> cent being rounded upward). Each calculation of the interest rate on the floating rate notes by the calculation agent will (in the absence of manifest error)
be final and binding on the noteholders and us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as any of the floating rate notes remains outstanding, there will at all times be a calculation
agent. Initially, The Bank of New York Mellon will act as calculation agent. We will make each interest payment to the holders of record of floating rate notes at the close of business on the March&nbsp;1, June&nbsp;1, September&nbsp;1 and
December&nbsp;1 immediately preceding the relevant interest payment date. The trustee, through its corporate trust office in the Borough of Manhattan, City of New York (in such capacity, the &#147;paying agent&#148;) will act as our paying agent
with respect to the floating rate notes. Payments of principal, interest and premium, if any, will be made by us through the paying agent to DTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
interest rate on the floating rate notes will in no event be higher than the maximum rate permitted by New York law as the same may be modified by United States laws of general application. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ranking </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will be unsecured general obligations
of Pfizer and will rank equally with all other unsecured and unsubordinated indebtedness of Pfizer from time to time outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will not be listed on any national securities exchange or be quoted on any automated dealer quotation system. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will contain a provision that
restricts our ability to consolidate with or merge into any other person or convey or transfer our properties and assets as an entirety or substantially as an entirety to any other person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The indenture will not restrict our ability to convey or transfer our properties and assets other than as an entirety or substantially as an entirety to any other person. See &#147;Description of
Debt Securities&#151;Consolidation, Merger or Sale&#148; in the accompanying prospectus. The indenture will not contain any other restrictive covenants, including those that would afford holders of the notes protection in the event of a
highly-leveraged transaction involving Pfizer or any of its affiliates or other events involving us that may adversely affect our creditworthiness or the value of the notes. The indenture also will not contain any covenants relating to total
indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders, current ratios or acquisitions and divestitures. The notes will not have the benefit of covenants that relate to subsidiary
guarantees, liens and sale leaseback transactions that apply to other of our existing unsecured and unsubordinated notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Further Issues </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pfizer may, without the consent of the holders of notes of any series, issue additional notes having the same ranking and the same interest rate, maturity and
other terms as the notes of any series (except for the issue date and the public offering price). Any additional notes having such similar terms, together with the notes of the applicable series, will constitute a single series of debt securities
under the indenture. No additional notes of any series may be issued if an event of default has occurred with respect to the notes of that series. Pfizer will not issue any additional notes intended to form a single series with the notes of any
series, unless such further notes will be fungible with all notes of the same series for U.S. federal income tax purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption of
Fixed Rate Notes; No Sinking Fund </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 notes may be redeemed at our option, in whole, at any time, or in part, from time to time. The redemption
price for the 2021 notes will be equal to the greater of the following amounts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">100% of the principal amount of the 2021 notes being redeemed on the redemption date; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sum of the present values of the remaining scheduled payments of principal and interest on the 2021 notes
being redeemed on that redemption date (not including the amount, if any, of accrued and unpaid interest to, but excluding, the redemption date) discounted to the redemption date on a semi-annual basis at the Treasury Rate (as defined below), as
determined by the Independent Investment Banker (as defined below), plus 5 basis points; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>plus</I>, in each case, accrued and unpaid
interest on the 2021 notes being redeemed to, but excluding, the redemption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our option, we may redeem the 2023 notes, the 2028 notes, the 2038
notes and the 2048 notes, in whole, at any time, or in part, from time to time, prior to August 15, 2023 (one month prior to the maturity date) with respect to the 2023 notes, June 15, 2028 (three months prior to the maturity date) with respect to
the 2028 notes, March 15, 2038 (six months prior to the maturity date) with respect to the 2038 notes and&nbsp;March 15, 2048 (six months prior to the maturity date) with respect to the 2048 notes. The redemption price for the 2023 notes, the 2028
notes, the 2038 notes and the 2048 notes will be equal to the greater of the following amounts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">100% of the principal amount of the fixed rate notes being redeemed on the redemption date; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sum of the present values of the remaining scheduled payments of principal and interest on the fixed rate
notes being redeemed on that redemption date (not including the amount, if any, of accrued and unpaid interest to, but excluding, the redemption date) discounted to the redemption date on a semi-annual basis at the Treasury Rate (as defined below),
as determined by the Independent Investment Banker (as defined below), plus 10 basis points in the case of the 2023 notes, plus 15 basis points in the case of the 2028 notes, plus 20 basis points in the case of the 2038 notes and plus 20&nbsp;basis
points in the case of the 2048 notes; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>plus</I>, in each case, accrued and unpaid interest on the 2023 notes, the 2028 notes, the
2038 notes and the 2048 notes being redeemed to, but excluding, the redemption date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time on or after&nbsp;August 15, 2023 (one month prior to the maturity date) with respect to the 2023
notes, June 15, 2028 (three months prior to the maturity date) with respect to the 2028 notes, March 15, 2038 (six months prior to the maturity date) with respect to the 2038 notes and&nbsp;March 15, 2048 (six months prior to the maturity date) with
respect to the 2048 notes, we may redeem such fixed rate notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the fixed rate notes to be redeemed, plus in each case, accrued and unpaid interest on the fixed rate
notes being redeemed to, but excluding, the redemption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, installments of interest on the applicable fixed rate notes
that are due and payable on interest payment dates falling on or prior to a redemption date will be payable on the interest payment date to the registered holders as of the close of business on the relevant record date according to the applicable
fixed rate notes and the indenture. The redemption prices for the fixed rate notes will be calculated on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will mail notice of any redemption at least 10 days, but not more than 60 days, before the redemption date to each registered holder of the fixed rate
notes to be redeemed. Once notice of redemption is mailed, the fixed rate notes called for redemption will become due and payable on the redemption date at the applicable redemption price, plus accrued and unpaid interest applicable to such fixed
rate notes to, but excluding, the redemption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any redemption notice may, at our discretion, be subject to one or more conditions precedent,
including completion of a corporate transaction. In such event, the related notice of redemption shall describe each such condition and, if applicable, shall state that, at our discretion, the date of redemption may be delayed until such time
(including more than 60 days after the notice of redemption was given) as any or all such conditions shall be satisfied or waived, or such redemption may not occur and such notice may be rescinded in the event that any or all such conditions shall
not have been satisfied (or waived by the Company in its sole discretion) by the date of redemption, or by the date of redemption as so delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
purposes of the foregoing discussion, the following definitions apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Comparable Treasury Issue&#148; means, for any series of fixed rate notes,
the United States Treasury security selected by the Independent Investment Banker as having a maturity comparable to the remaining term of the fixed rate notes of such series to be redeemed that would be utilized, at the time of selection and in
accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the fixed rate notes of such series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Comparable Treasury Price&#148; means, with respect to any redemption date and series of fixed rate notes to be redeemed, (A)&nbsp;the average of the
Reference Treasury Dealer Quotations for such redemption date and series, after excluding the highest and lowest of such Reference Treasury Dealer Quotations, or (B)&nbsp;if the Independent Investment Banker obtains fewer than four such Reference
Treasury Dealer Quotations, the average of such Reference Treasury Dealer Quotations, or (C)&nbsp;if only one Reference Treasury Dealer Quotation is received, such Reference Treasury Dealer Quotation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Independent Investment Banker&#148; means one of the Reference Treasury Dealers appointed by us to act as the &#147;Independent Investment Banker.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Reference Treasury Dealer&#148; means each of Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, Merrill Lynch, Pierce,
Fenner&nbsp;&amp; Smith Incorporated and Morgan Stanley&nbsp;&amp; Co. LLC (or their respective affiliates that are Primary Treasury Dealers), and their respective successors; provided, however, that if any of the foregoing shall cease to be a
primary U.S. Government securities dealer in the United States (a &#147;Primary Treasury Dealer&#148;), we will substitute therefor another Primary Treasury Dealer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Reference Treasury Dealer Quotation&#148; means, with respect to each Reference Treasury Dealer and any redemption date and series of fixed rate notes
to be redeemed, the average, as determined by the Independent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investment Banker, of the bid and asked prices for the Comparable Treasury Issue for such series (expressed in each case as a percentage of its principal amount) quoted in writing to the
Independent Investment Banker by such Reference Treasury Dealer at 5:00 p.m. (New York City Time) on the third business day preceding such redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Treasury Rate&#148; means, with respect to any redemption date for any series of fixed rate notes, the rate per annum equal to the semi-annual
equivalent yield to maturity of the applicable Comparable Treasury Issue, assuming a price for such Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the applicable Comparable Treasury Price for such redemption
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On and after the redemption date, interest will cease to accrue on the fixed rate notes or any portion of the fixed rate notes called for
redemption (unless we default in the payment of the redemption price and accrued and unpaid interest). On or before the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the redemption price of and accrued
and unpaid interest on the fixed rate notes to be redeemed on that date. If fewer than all of the fixed rate notes of any series are to be redeemed, the fixed rate notes to be redeemed shall be selected pro rata, by lot or by such other method as
the trustee shall deem fair and appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not redeem the floating rate notes at our option prior to maturity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are not entitled to the benefit of a sinking fund. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry System </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Depository Trust Company
(&#147;DTC&#148;), New York, New York, will act as securities depositary for the notes. Each series of notes will be issued as fully registered securities registered in the name of Cede&nbsp;&amp; Co. (DTC&#146;s partnership nominee) or such other
name as may be requested by an authorized representative of DTC. One or more fully-registered global note certificates will be issued for each series of notes, in the aggregate principal amount of such issue, and will be deposited with DTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial interests in the notes will be shown on, and transfers thereof will be effected only through, records maintained by DTC and its direct and indirect
participants, including Euroclear Bank S.A./N.V., as operator of the Euroclear System (&#147;Euroclear&#148;) and Clearstream Banking, soci&eacute;t&eacute; anonyme, Luxembourg (&#147;Clearstream Banking&#148;). Investors may elect to hold interests
in the notes through any of DTC, Euroclear or Clearstream Banking, if they are participants in these systems, or indirectly through organizations which are participants in these systems. Euroclear and Clearstream Banking hold securities on behalf of
their participants through customers&#146; securities accounts in their respective names on the books of their respective depositaries, which in turn hold the securities in customers&#146; securities accounts in the depositaries&#146; names on the
books of DTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC has informed us that DTC is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited-purpose trust company organized under the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;banking organization&#148; within the meaning of the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing agency&#148; registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Euroclear and Clearstream Banking have informed us that: Euroclear and Clearstream Banking each hold securities for their customers and
facilitate the clearance and settlement of securities transactions by electronic book-entry transfer between their respective account holders. Euroclear and Clearstream Banking provide various services including safekeeping, administration,
clearance and settlement of internationally traded securities and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities lending and borrowing. Euroclear and Clearstream Banking also deal with domestic securities markets in several countries through established depositary and custodial relationships.
Euroclear and Clearstream Banking have established an electronic bridge between their two systems across which their respective participants may settle trades with each other. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Euroclear and Clearstream Banking customers are world-wide financial institutions including underwriters, securities brokers and dealers, banks, trust
companies and clearing corporations. Indirect access to Euroclear and Clearstream Banking is available to other institutions, which clear through or maintain a custodial relationship with an account holder of either system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC holds securities that its participants (&#147;Direct Participants&#148;) deposit with DTC. DTC also facilitates the settlement among Direct Participants
of securities transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in Direct Participants&#146; accounts, which eliminates the need for physical movement of securities certificates.
Direct Participants include securities brokers and dealers, banks, trust companies, clearing corporations, and certain other organizations. DTC is a wholly-owned subsidiary of The Depository Trust&nbsp;&amp; Clearing Corporation (&#147;DTCC&#148;).
DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system is
also available to others such as securities brokers and dealers, banks, and trust companies that clear through or maintain a custodial relationship with a Direct Participant, either directly or indirectly (&#147;Indirect Participants&#148;). The
rules applicable to DTC and its Direct and Indirect Participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases of notes under the DTC system must be made by or
through Direct Participants, which receive a credit for the notes on DTC&#146;s records. The ownership interest of each actual purchaser of each note (&#147;Beneficial Owner&#148;) is in turn to be recorded on the Direct and Indirect
Participants&#146; records. Beneficial Owners will not receive written confirmations from DTC of their purchase, but Beneficial Owners are expected to receive written confirmations providing details of the transaction, as well as periodic statements
of their holdings, from the Direct or Indirect Participant through which the Beneficial Owner entered into the transaction. Transfers of ownership interests in the notes are to be accomplished by entries made on the books of Direct and Indirect
Participants acting on behalf of Beneficial Owners. Beneficial Owners will not receive certificates representing their ownership interests in the notes except in the event that use of the book-entry system for the notes is discontinued. As a result,
the ability of a person having a beneficial interest in the notes to pledge such interest to persons or entities that do not participate in the DTC system, or to otherwise take actions with respect to such interest, may be affected by the lack of a
physical certificate evidencing such interest. In addition, the laws of some states require that certain persons take physical delivery in definitive form of securities that they own and that security interests in negotiable instruments can only be
perfected by delivery of certificates representing the instruments. Consequently, the ability to transfer notes evidenced by the global notes will be limited to such extent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To facilitate subsequent transfers, all notes deposited by Direct Participants with DTC are registered in the name of DTC&#146;s partnership nominee,
Cede&nbsp;&amp; Co. or such other name as may be requested by an authorized representative of DTC. The deposit of notes with DTC and their registration in the name of Cede&nbsp;&amp; Co. or such other nominee do not effect any change in beneficial
ownership. DTC has no knowledge of the actual Beneficial Owners of the notes; DTC&#146;s records reflect only the identity of the Direct Participants to whose accounts such notes are credited, which may or may not be the Beneficial Owners. The
Direct and Indirect Participants will remain responsible for keeping account of their holdings on behalf of their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conveyance of notices and
other communications by DTC to Direct Participants, by Direct Participants to Indirect Participants, and by Direct Participants and Indirect Participants to Beneficial Owners will be governed by arrangements among them, subject to any statutory or
regulatory requirements as may be in effect from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Owners of notes may wish to take certain steps to augment the transmission to them of notices of
significant events with respect to the notes, such as redemptions, tenders, defaults, and proposed amendments to the documents related to the notes. For example, Beneficial Owners of notes may wish to ascertain that the nominee holding the notes for
their benefit has agreed to obtain and transmit notices to Beneficial Owners. In the alternative, Beneficial Owners may wish to provide their names and addresses to the registrar and request that copies of notices be provided directly to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redemption notices will be sent to DTC. If less than all of the notes within a series are being redeemed, DTC&#146;s practice is to determine by lot the
amount of the interest of each Direct Participant in such issue to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither DTC nor Cede&nbsp;&amp; Co. (nor such other DTC nominee) will
consent or vote with respect to the notes. Under its usual procedures, DTC mails an Omnibus Proxy to the issuer as soon as possible after the record date. The Omnibus Proxy assigns Cede&nbsp;&amp; Co.&#146;s consenting or voting rights to those
Direct Participants to whose accounts the notes are credited on the record date (identified in a listing attached to the Omnibus Proxy). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments of
principal, interest and premium, if any, on the notes will be made to Cede&nbsp;&amp; Co., or such other nominee as may be requested by an authorized representative of DTC. DTC&#146;s practice is to credit Direct Participants&#146; accounts, upon
DTC&#146;s receipt of funds and corresponding detail information from us on the payable date in accordance with their respective holdings shown on DTC&#146;s records. Payments by Participants to Beneficial Owners will be governed by standing
instructions and customary practices, as is the case with securities held for the accounts of customers in bearer form or registered in &#147;street name&#148; and will be the responsibility of such Participant and not of DTC, or us, subject to any
statutory or regulatory requirements as may be in effect from time to time. Payment of redemption proceeds to Cede&nbsp;&amp; Co. (or such other nominee as may be requested by an authorized representative of DTC) is our responsibility and
disbursement of such payments to Direct Participants will be the responsibility of DTC, and disbursement of such payments to the Beneficial Owners will be the responsibility of Direct and Indirect Participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors electing to hold their notes through DTC will follow the settlement practices applicable to U.S. corporate debt obligations. The securities custody
accounts of investors will be credited with their holdings on the settlement date against payment in <FONT STYLE="white-space:nowrap">same-day</FONT> funds within DTC effected in U.S. dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors electing to hold their notes through Euroclear or Clearstream Banking accounts will follow the settlement procedures applicable to conventional
eurobonds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Secondary market sales of book-entry interests in the notes between DTC participants will occur in the ordinary way in accordance with DTC
rules and will be settled using the procedures applicable to United States corporate debt obligations in DTC&#146;s Settlement System. Secondary market sales of book-entry interests in the notes held through Euroclear or Clearstream Banking to
purchasers of book-entry interests in the notes through Euroclear or Clearstream Banking will be conducted in accordance with the normal rules and operating procedures of Euroclear and Clearstream Banking and will be settled using the procedures
applicable to conventional eurobonds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC may discontinue providing its services as securities depositary with respect to the notes at any time by giving
reasonable notice to us. Under such circumstances, in the event that a successor securities depositary is not obtained, note certificates are required to be printed and delivered. In addition, we may decide to discontinue use of the system of
book-entry transfers through DTC (or a successor securities depositary). In that event, note certificates will be printed and delivered. See &#147;Description of Debt Securities&#151;Global Securities&#148; in the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not have any responsibility or obligation to participants in the DTC system or the persons for whom they act as nominees with respect to the accuracy
of the records of DTC, its nominee or any Direct or Indirect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant with respect to any ownership interest in the notes, or with respect to payments to or providing of notice for the Direct Participants, the Indirect Participants or the beneficial
owners of the notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this section concerning DTC, Euroclear, Clearstream Banking and their book-entry systems has been obtained from
sources that we believe to be reliable. Neither we, the trustee nor the underwriters, dealers or agents are responsible for the accuracy or completeness of this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_7"></A>U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of U.S. federal income tax considerations generally applicable to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders (as defined below) with respect to an investment in the notes as of the date hereof. Unless otherwise noted, this summary deals only with notes that are held as capital assets within the meaning of the U.S. Internal Revenue Code of 1986, as
amended (the &#147;Code&#148;) (generally property held for investment) by a holder that acquired the notes upon original issuance at their initial offering price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary does not address all aspects of U.S. federal income taxation that may be relevant to a particular holder in light of that holder&#146;s
particular circumstances, or to certain types of holders subject to special treatment under U.S. federal income tax law (e.g., financial institutions, insurance companies, controlled foreign corporations, passive foreign investment companies,
partnerships or other pass-through entities, expatriates or former long-term residents of the United States, persons subject to the alternative minimum tax, accrual basis taxpayers subject to special tax accounting rules pursuant to
Section&nbsp;451(b) of the Code, individual retirement accounts or other <FONT STYLE="white-space:nowrap">tax-deferred</FONT> accounts, broker-dealers or other dealers in securities or currencies, traders in securities that elect to use a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings, persons holding notes as a position in a &#147;straddle,&#148; or as part of a synthetic security or
&#147;hedge,&#148; &#147;conversion transaction,&#148; &#147;constructive sale&#148; or other integrated investment, and <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations). Furthermore, this summary does not address other U.S. federal
tax consequences (e.g., estate or gift tax or the Medicare tax on net investment income) or tax consequences arising under the tax laws of any state, locality or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, its legislative history, existing and proposed regulations, and published rulings and court decisions, all as in effect
as of the date hereof, and all of which are subject to change, possibly with retroactive effect, which could alter the U.S. federal income tax consequences described below. No ruling from the Internal Revenue Service (&#147;IRS&#148;) has been or
will be sought on any of the issues discussed herein, and there can be no assurance that the IRS or a court will concur with the conclusions reached below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this summary, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is a beneficial owner of notes (other than a partnership
or other entity or arrangement classified as a partnership for U.S. federal income tax purposes) that is not a U.S. Holder. A &#147;U.S. Holder&#148; is a beneficial owner of notes that is for U.S. federal income tax purposes, (i)&nbsp;an individual
citizen or resident of the United States, (ii)&nbsp;a corporation (or other entity that is treated as a corporation for U.S. federal income tax purposes) that is created or organized in or under the laws of the United States or any state or
political subdivision thereof, (iii)&nbsp;an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source, or (iv)&nbsp;a trust if (a)&nbsp;it is subject to the primary supervision of a court
within the United States and one or more United States persons are authorized to control all of its substantial decisions or (b)&nbsp;it has a valid election in effect under applicable United States Treasury regulations to be treated as a United
States person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a partnership (or other entity or arrangement classified as a partnership for U.S. federal income tax purposes) holds notes, the tax
treatment of a partner in such partnership generally will depend on the status of the partner and the activities of the partnership. Partnerships and other entities or arrangements that are classified as partnerships for U.S. federal income tax
purposes and persons holding notes through any such entity should consult an independent tax advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EACH PROSPECTIVE INVESTOR SHOULD CONSULT AN
INDEPENDENT TAX ADVISOR AS TO THE U.S. FEDERAL, STATE, LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.,</FONT> AND ANY OTHER TAX CONSEQUENCES TO IT OF AN INVESTMENT IN THE NOTES. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under the
heading &#147;Additional Withholding Requirements under the Foreign Account Tax Compliance Act,&#148; a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal withholding tax
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on interest received on the notes, provided that such interest is not effectively connected with such holder&#146;s conduct of a trade or business in the United States and such holder
(i)&nbsp;does not own, actually or constructively, 10% or more of the total combined voting power of all classes of our stock entitled to vote, (ii)&nbsp;is not a controlled foreign corporation directly or indirectly related to us within the meaning
of Section&nbsp;881(c)(3)(C) of the Code and (iii)&nbsp;satisfies certain certification requirements under penalty of perjury as to its status as a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (generally through the provision of a
properly completed and executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other applicable IRS form). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described in the preceding paragraph, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income
tax on interest received on the notes, unless such interest is effectively connected with the conduct by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of a trade or business in the United States (and, if an applicable treaty so
requires, is attributable to the conduct of a trade or business through a permanent establishment or fixed base in the United States). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is subject to U.S. federal income tax on interest
under the rules described in the preceding sentence will not be subject to U.S. federal withholding tax on any such interest if the holder satisfies certain certification requirements under penalty of perjury (generally through the provision of a
properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> or other applicable form). Interest that is effectively connected with the conduct by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of a trade or business in the
United States (and, if an applicable treaty so requires, is attributable to the conduct of a trade or business through a permanent establishment or fixed base in the United States) will be subject to U.S. federal income tax on a net basis. In
addition, if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a foreign corporation, such holder may also be subject to a branch profits tax at a rate of 30% (or lower treaty rate, if applicable) on its effectively connected earnings
and profits for the taxable year, subject to certain adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not qualify for an
exemption from U.S. federal withholding tax under the rules described above will generally be subject to withholding at a rate of 30% (or lower treaty rate, if applicable) on interest received on the notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale, Exchange, Retirement or Other Disposition of the Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under the heading &#147;Additional Withholding Requirements under the Foreign Account Tax Compliance Act,&#148; gain realized
by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder on the sale, exchange, retirement, or other disposition of the notes (other than amounts that represent accrued but unpaid interest, which will be subject to the rules regarding interest
described above) generally will not be subject to U.S. federal withholding tax. Such gain also generally will not be subject to U.S. federal income tax, unless the gain is effectively connected with the conduct by the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of a trade or business in the United States (and, if an applicable treaty so requires, is attributable to the conduct of a trade or business through a permanent establishment or fixed base in
the United States) or, in the case of gain realized by an individual <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is present in the United States for 183 days or more in the
taxable year of the disposition and certain other conditions are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain that is effectively connected with the conduct by a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of a trade or business in the United States (and, if an applicable treaty so requires, is attributable to the conduct of a trade or business through a permanent establishment or fixed base in the
United States) will be subject to U.S. federal income tax on a net basis. In addition, if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a foreign corporation, such holder may also be subject to a branch profits tax at a rate of 30%
(or lower treaty rate, if applicable) on its effectively connected earnings and profits for the taxable year, subject to certain adjustments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional Withholding Requirements under the Foreign Account Tax Compliance Act </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sections 1471 through 1474 of the Code and the Treasury regulations and administrative guidance promulgated thereunder (commonly referred to as the
&#147;Foreign Account Tax Compliance Act&#148; or &#147;FATCA&#148;) generally impose withholding at a rate of 30% in certain circumstances on interest payable on and, after December&nbsp;31, 2018, gross proceeds from the disposition of, notes held
by or through certain financial institutions (including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investment funds), unless such institution (i)&nbsp;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts
maintained by, the institution that are owned by certain U.S. persons or by certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (ii)&nbsp;if
required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental
agreement between the United States and an applicable foreign country may modify these requirements. Accordingly, the entity through which notes are held will affect the determination of whether such withholding is required. Similarly, interest
payable on and, after December&nbsp;31, 2018, gross proceeds from the disposition of, notes held by an investor that is a <FONT STYLE="white-space:nowrap">non-financial</FONT> <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity that does not
qualify under certain exemptions generally will be subject to withholding at a rate of 30%, unless such entity either (i)&nbsp;certifies that such entity does not have any &#147;substantial United States owners&#148; or (ii)&nbsp;provides certain
information regarding the entity&#146;s &#147;substantial United States owners,&#148; which the payor will generally be required to provide to the IRS. Each prospective investor is urged to consult its tax advisor regarding the possible implications
of these rules on an investment in the notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_8"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement and related pricing agreement, each dated&nbsp;September 4, 2018, among us and the
underwriters in the table below, for whom Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Morgan Stanley&nbsp;&amp; Co. LLC are acting as representatives, we have
agreed to sell to each of the underwriters, and each such underwriter has severally, and not jointly, agreed to purchase from us, the aggregate principal amount of the notes set forth opposite its name below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount of<BR>Floating<BR>Rate Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount of<BR>2021 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount of<BR>2023 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount of<BR>2028 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount of<BR>2038 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount of<BR>2048 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Credit Suisse Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner &amp; Smith</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Morgan Stanley &amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Barclays Capital Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Goldman Sachs &amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">HSBC Securities (USA) Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deutsche Bank Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Santander Investment Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">RBC Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Academy Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Samuel A. Ramirez &amp; Company, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Siebert Cisneros Shank &amp; Co., L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">The Williams Capital Group, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">700,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are committed to take and pay for all of the notes being offered, if any are taken. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the notes of each series directly to the public at the applicable public offering prices set forth on the cover page of this
prospectus supplement and may offer the notes to certain dealers at that public offering prices less concessions not in excess of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.200% of the principal amount in the case of the floating rate notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.150% of the principal amount in the case of the 2021 notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.200% of the principal amount in the case of the 2023 notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.250% of the principal amount in the case of the 2028 notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.450% of the principal amount in the case of the 2038 notes; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.450% of the principal amount in the case of the 2048 notes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters may allow, and such dealers may reallow, concessions to certain other dealers not in excess of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.100% of the principal amount in the case of the floating rate notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.100% of the principal amount in the case of the 2021 notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.100% of the principal amount in the case of the 2023 notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.150% of the principal amount in the case of the 2028 notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.250% of the principal amount in the case of the 2038 notes; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0.250% of the principal amount in the case of the 2048 notes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the initial offering of the notes to the public, the representatives of the underwriters may change
the public offering prices and concessions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the underwriting discounts that we are to pay to the underwriters in connection
with this offering (expressed as a percentage of the principal amount of the notes). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per floating rate note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.350</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per 2021 note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per 2023 note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.350</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per 2028 note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.450</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per 2038 note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.750</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per 2048 note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.750</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities
Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are offering the notes,
subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, including the validity of the notes, and other conditions contained in the underwriting agreement, such as the receipt by
the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell notes in the open market. Purchases and sales in the open market may include short
sales, purchases to cover short positions and stabilizing purchases. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Short sales involve secondary market sales by the underwriters of a greater number of notes than they are
required to purchase in the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Covering transactions involve purchases of notes in the open market after the distribution has been completed in
order to cover short positions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stabilizing transactions involve bids to purchase notes so long as the stabilizing bids do not exceed a specified
maximum. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases to cover short positions and stabilizing purchases, as well as other purchases by the underwriters for their own
accounts, may have the effect of preventing or retarding a decline in the market prices of the notes. They may also cause the prices of the notes to be higher than the price that would otherwise exist in the open market in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. If the underwriters commence any of these transactions, they may discontinue them at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading,
commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and services.
Certain of the underwriters and their affiliates have provided, and in the future may provide, certain investment and commercial banking and financial advisory services from time to time for us and our affiliates in the ordinary course of business
for which they have received, and in the future would receive, customary fees and commissions. In addition, certain of the underwriters and their affiliates may act as agents or lenders under our credit facilities and hold positions in our
outstanding securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers,
directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the
accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of ours or our affiliates (directly, as collateral securing other obligations
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or otherwise) and/or persons and entities with relationships with us. If any of the underwriters or their affiliates has a lending relationship with us, certain of those underwriters or their
affiliates routinely hedge, and certain other of those underwriters or their affiliates may hedge, their credit exposure to us consistent with their customary risk management policies. Typically, these underwriters and their affiliates would hedge
such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities, including potentially the notes offered hereby. Any such credit default swaps or short
positions could adversely affect future trading prices of the notes offered hereby. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express
independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no public trading markets for the notes, and we do not intend to apply for listing of the notes on any national securities exchange or for quotation
of the notes on any automated dealer quotation system. We have been advised by the underwriters that they presently intend to make a market in the notes of each series after the consummation of the offering, although they are under no obligation to
do so and may discontinue any market-making activities at any time without any notice. Prior to the offering, there have been no active trading markets for the notes. No assurance can be given as to the existence or the liquidity of any trading
markets for the notes or that active public trading markets for the notes will develop. If active trading markets for the notes do not develop, the market prices and liquidity of the notes may be adversely affected. If the notes of any series are
traded, they may trade at a discount from their initial offering price, depending on prevailing interest rates, the market for similar securities, our performance and certain other factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to deliver the notes against payment for the notes on or about the date specified in the last paragraph of the cover page of this prospectus
supplement, which will be the third business day following the pricing of the notes. Since trades in the secondary market generally settle in two business days, purchasers who wish to trade notes prior to the delivery of the notes hereunder will be
required, by virtue of the fact that the notes will settle in T+3, to specify alternative settlement arrangements at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to their date
of delivery hereunder should consult their advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that our expenses in connection with this offering, excluding underwriting discounts and
commissions, will be approximately $5 million. The underwriters have agreed to reimburse us for certain of our expenses in connection with the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the European Economic Area </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail
investor in the European Economic Area (&#147;EEA&#148;). For these purposes, a retail investor means a person who is one (or more) of: (i)&nbsp;a retail client as defined in point (11)&nbsp;of Article 4(1) of Directive 2014/65/EU (as amended,
&#147;MiFID II&#148;); or (ii)&nbsp;a customer within the meaning of Directive 2002/92/EC (as amended, the &#147;Insurance Mediation Directive&#148;), where that customer would not qualify as a professional client as defined in point (10)&nbsp;of
Article 4(1) of MiFID II; or (iii)&nbsp;not a qualified investor as defined in Directive 2003/71/EC (as amended, the &#147;Prospectus Directive&#148;). Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended,
the &#147;PRIIPs Regulation&#148;) for offering or selling the notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the notes or otherwise making them available to any retail
investor in the EEA may be unlawful under the PRIIPs Regulation. This prospectus supplement has been prepared on the basis that any offer of Notes in any Member State of the EEA will be made pursuant to an exemption under the Prospectus Directive
from the requirement to publish a prospectus for offers of Notes. This prospectus supplement is not a prospectus for the purposes of the Prospectus Directive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed
at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19 (5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such
persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment activity to which
this document relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in France </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this prospectus supplement nor any other offering material relating to the notes described in this prospectus supplement has been submitted to the
clearance procedures of the <I>Autorit&eacute; des March&eacute;s Financiers</I> or of the competent authority of another member state of the European Economic Area and notified to the <I>Autorit&eacute; des March&eacute;s Financiers</I>. The notes
have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus supplement nor any other offering material relating to the notes has been or will be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">released, issued, distributed or caused to be released, issued or distributed to the public in France; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">used in connection with any offer for subscription or sale of the notes to the public in France.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such offers, sales and distributions will be made in France only: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to qualified investors (<I>investisseurs qualifi&eacute;s</I>) and/or to a restricted circle of investors
(<I>cercle restreint d&#146;investisseurs</I>), in each case investing for their own account, all as defined in, and in accordance with, articles <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.411-1,</FONT> <FONT
STYLE="white-space:nowrap">D.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.734-1,</FONT> <FONT STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the
French <I>Code mon&eacute;taire et financier</I>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to investment services providers authorized to engage in portfolio management on behalf of third parties; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in a transaction that, in accordance with article <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.411-2-II-1&deg;-or-2&deg;-or</FONT></FONT></FONT></FONT></FONT></FONT> 3&deg; of the
French <I>Code mon&eacute;taire et financier</I> and article <FONT STYLE="white-space:nowrap">211-2</FONT> of the General Regulations (<I>R&egrave;glement G&eacute;n&eacute;ral</I>) of the <I>Autorit&eacute; des March&eacute;s Financiers</I>, does
not constitute a public offer (<I>appel public &agrave; l&#146;&eacute;pargne</I>). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes may be resold directly or indirectly,
only in compliance with articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> and <FONT STYLE="white-space:nowrap">L.621-8</FONT> through <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the French <I>Code mon&eacute;taire et financier</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective lnvestors in Switzerland </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is not intended to constitute an offer or solicitation to purchase or invest in the
notes described herein in Switzerland. The notes may not be publicly offered, sold or advertised, directly or indirectly, in, into or from Switzerland and will not be listed on the SIX Swiss Exchange or on any other exchange or regulated trading
facility in Switzerland. Neither this prospectus supplement nor any other offering or marketing material relating to the notes constitutes a prospectus as such term is understood pursuant to article 652a or article 1156 of the Swiss Code of
Obligations, and neither this prospectus supplement nor any other offering or marketing material relating to the notes may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes
may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder, or
(iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating to the notes may be
issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if
permitted to do so under the laws of Hong Kong) other than with respect to notes which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning of the Securities and
Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes offered in this prospectus supplement have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law
No.&nbsp;25 of 1948, as amended). The notes have not been offered or sold and will not be offered or sold, directly or indirectly, in Japan or to or for the account of any resident of Japan, except (i)&nbsp;pursuant to an exemption from the
registration requirements of the Securities and Exchange Law and (ii)&nbsp;in compliance with any other applicable requirements of Japanese law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus supplement and any other document or material in connection with the offer or sale, or invitation for subscription
or purchase, of the notes may not be circulated or distributed, nor may the notes be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than
(i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to
Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to
compliance with conditions set forth in the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the notes are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which
is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business
of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">shares, debentures and units of shares and debentures of that
corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the notes pursuant to an offer made under Section&nbsp;275 of
the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor (for corporations, under Section&nbsp;274 of the SFA) or to a relevant person
defined in Section&nbsp;275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such rights and interest in that trust are acquired at a
consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the
conditions specified in Section&nbsp;275 of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National
Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT>
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the notes must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI
<FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Margaret M. Madden, our Senior Vice President and Corporate Secretary, Chief Governance Counsel, will pass upon the validity of the notes. Ms.&nbsp;Madden
beneficially owns, or has the right to acquire under our employee benefit plans, an aggregate of less than 1% of the outstanding shares of our common stock. Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP, New York, New York, is also acting as
legal counsel to us in connection with this offering. Simpson Thacher&nbsp;&amp; Bartlett LLP, New York, New York will pass upon various legal matters for the underwriters relating to the offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Pfizer Inc. and Subsidiary Companies as of December&nbsp;31, 2017 and 2016, and for each of the years in the
three-year period ended December&nbsp;31, 2017, and management&#146;s assessment of the effectiveness of internal control over financial reporting as of December&nbsp;31, 2017 have been incorporated by reference herein and in the registration
statement in reliance upon the reports of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the unaudited interim financial information for the periods ended July&nbsp;1, 2018 and July&nbsp;2, 2017 and April&nbsp;1, 2018 and
April&nbsp;2, 2017, incorporated by reference herein, the independent registered public accounting firm has reported that they applied limited procedures in accordance with professional standards for a review of such information. However, their
separate reports included in the Company&#146;s quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended July&nbsp;1, 2018 and April&nbsp;1, 2018, and incorporated by reference herein, states that they did not
audit and they do not express an opinion on that interim financial information. Accordingly, the degree of reliance on their reports on such information should be restricted in light of the limited nature of the review procedures applied. The
accountants are not subject to the liability provisions of Section&nbsp;11 of the Securities Act for their reports on the unaudited interim financial information because none of those reports is a &#147;report&#148; or a &#147;part&#148; of the
registration statement prepared or certified by the accountants within the meaning of Sections 7 and 11 of the Securities Act. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom617367_11">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the SEC. You may
read and copy any reports, statements or other information on file at the SEC&#146;s public reference room at 100 F Street, N.E., Washington, D.C., 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the public reference room. The SEC filings are also available to the public from commercial document retrieval services. These filings are also available at
the Internet website maintained by the SEC at <I>http://www.sec.gov</I>. The filings are also available on our website at <I>http://www.pfizer.com</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS SUPPLEMENT INCORPORATES DOCUMENTS BY REFERENCE WHICH ARE NOT PRESENTED IN OR DELIVERED WITH THIS PROSPECTUS SUPPLEMENT. YOU SHOULD RELY
ONLY ON THE INFORMATION CONTAINED IN THIS PROSPECTUS SUPPLEMENT AND IN THE DOCUMENTS THAT WE HAVE INCORPORATED BY REFERENCE IN THIS PROSPECTUS SUPPLEMENT. WE HAVE NOT, AND THE UNDERWRITERS HAVE NOT, AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION
THAT IS DIFFERENT FROM OR IN ADDITION TO THE INFORMATION CONTAINED IN THIS PROSPECTUS SUPPLEMENT, THE ACCOMPANYING PROSPECTUS AND IN THE DOCUMENTS THAT WE HAVE INCORPORATED BY REFERENCE IN THIS PROSPECTUS SUPPLEMENT AND THE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
ACCOMPANYING PROSPECTUS AND ANY FREE WRITING PROSPECTUS THAT WE MAY PROVIDE YOU IN CONNECTION WITH THIS OFFERING. WE AND THE UNDERWRITERS TAKE NO RESPONSIBILITY FOR, AND CAN PROVIDE NO ASSURANCE
AS TO THE RELIABILITY OF, ANY OTHER INFORMATION THAT OTHERS MAY GIVE YOU. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate information into this prospectus supplement by reference,
which means that we disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus supplement, except to the extent
superseded by information contained in this prospectus supplement, the accompanying prospectus or by information contained in documents filed with the SEC after the date of this prospectus supplement. This prospectus supplement incorporates by
reference the documents set forth below that have been previously filed with the SEC; provided, however, that we are not incorporating any documents or information deemed to have been furnished rather than filed in accordance with SEC rules. These
documents contain important information about us and our financial condition. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pfizer&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2017 filed February&nbsp;22, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pfizer&#146;s Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods
ended April&nbsp;1, 2018 filed May&nbsp;10, 2018 and July&nbsp;1, 2018 filed August&nbsp;9, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Portions of Pfizer&#146;s Definitive Proxy Statement on Schedule 14A filed March&nbsp;15, 2018, that are
incorporated by reference into Part III of Pfizer&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pfizer&#146;s Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed February&nbsp;23, 2018,
March&nbsp;6, 2018 and May&nbsp;1, 2018 (only Item 5.07). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings made with the SEC
pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus supplement and the date all of the securities offered by this prospectus supplement are sold or the offering is otherwise terminated, with the
exception of any information furnished under Item 2.02 and Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which is not deemed filed and which is not incorporated by reference in this prospectus supplement. Any such filings shall be
deemed to be incorporated by reference and to be a part of this prospectus supplement from the respective dates of filing of those documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will
provide without charge upon written or oral request to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any and all of the documents which are incorporated by reference in this prospectus supplement but not
delivered with this prospectus supplement (other than exhibits unless such exhibits are specifically incorporated by reference in such documents). You may request a copy of these documents by writing or telephoning us at: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Senior Vice President and Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pfizer Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 East 42nd Street
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10017-5703 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(212)
<FONT STYLE="white-space:nowrap">733-2323</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The information contained on our website, our Facebook, YouTube and LinkedIn pages or
our Twitter accounts does not, and shall not be deemed to, constitute a part of this prospectus supplement. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g617367g94r49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>PFIZER INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>DEBT SECURITIES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>COMMON
STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PREFERRED STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WARRANTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>DEPOSITARY
SHARES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE CONTRACTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE UNITS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>GUARANTEES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from
time to time offer to sell debt securities, common stock, preferred stock, warrants, depositary shares, purchase contracts, purchase units or guarantees. Each time we sell securities pursuant to this prospectus, we will provide a supplement to this
prospectus that contains specific information about the offering and the specific terms of the securities offered. The prospectus supplement may also add to, update or change information contained in this prospectus. In addition, we may supplement,
update or change any of the information contained in this prospectus by incorporating information by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, selling securityholders to be named in a prospectus supplement may offer our securities from time to time. To the extent that any selling securityholder resells any securities, the selling securityholder may be required to provide you with
this prospectus and a prospectus supplement identifying and containing specific information about the selling securityholder and the terms of the securities being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, the supplements to this prospectus and any incorporated documents carefully before you invest in any of our
securities. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell securities to or through one or more underwriters, dealers and agents, or directly to purchasers. The names and
compensation of any underwriters or agents involved in the sale of securities will be described in a supplement to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on the New York Stock Exchange under the symbol &#147;PFE.&#148; If we decide to seek a listing of any securities offered by this prospectus, the applicable prospectus supplement will disclose the exchange or market on which
such securities will be listed, if any, or where we have made an application for listing, if any. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in
our securities involves risk. You should carefully consider the risk factors incorporated in this prospectus by reference and described under the heading &#147;<A HREF="#toc617367_4">Risk Factors</A>&#148; beginning on page&nbsp;4. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR
DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this
prospectus is February&nbsp;26, 2018. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_2">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_5">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_8">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_9">DESCRIPTION OF OTHER SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_10">SELLING SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc617367_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>No person is authorized to give any information or to make any representations other than those contained
or incorporated by reference in this prospectus, any accompanying prospectus supplement or any free writing prospectus we may provide you in connection with an offering. We take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. This prospectus and any accompanying prospectus supplement are not an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction where it is unlawful.
Neither the delivery of this prospectus or any accompanying prospectus supplement, nor any sale of securities made under these documents, will, under any circumstances, create any implication that there has been no change in our affairs since the
date of this prospectus, any accompanying prospectus supplement or any free writing prospectus we may provide you in connection with an offering or that the information contained or incorporated by reference is correct as of any time subsequent to
the date of such information. You should assume that the information in this prospectus or any accompanying prospectus supplement, as well as the information incorporated by reference in this prospectus or any accompanying prospectus supplement, is
accurate only as of the date of the documents containing the information, unless the information specifically indicates that another date applies. Our business, financial condition, results of operations and prospects may have changed since those
dates. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of an &#147;automatic shelf&#148; registration statement that we filed with the Securities and Exchange Commission
(the SEC), as a &#147;well-known seasoned issuer&#148; as defined in Rule&nbsp;405 under the Securities Act of 1933, as amended (the Securities Act) using a &#147;shelf&#148; registration process. We may sell any combination of the securities
described in this prospectus from time to time in one or more offerings, and selling securityholders may offer such securities owned by them from time to time. You should carefully read this prospectus and any accompanying prospectus supplement
together with the additional information described under the heading &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
provides you with a general description of the securities that may be offered by us and/or selling securityholders. Each time we sell securities pursuant to this prospectus, we will provide a prospectus supplement that contains specific information
about the terms of that offering, including the specific amounts, prices and terms of the securities offered. If this prospectus is inconsistent with the prospectus supplement, you should rely upon the prospectus supplement. In addition, the
prospectus supplement may also add, update or change the information contained in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are in a jurisdiction where
offers to sell, or solicitations of offers to purchase, the securities offered by this document are unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this document does not
extend to you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wherever references are made in this prospectus to information that will be included in a prospectus supplement, to the
extent permitted by applicable law, rules or regulations, we may instead include such information or add, update or change the information contained in this prospectus by means of a post-effective amendment to the registration statement of which
this prospectus is a part, through filings we make with the SEC that are incorporated by reference in this prospectus or by any other method as may then be permitted under applicable law, rules or regulations. For purposes of this prospectus, any
reference to a prospectus supplement may also refer to a free writing prospectus unless the context requires otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References in
this prospectus to &#147;Pfizer,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; are to Pfizer Inc. and its consolidated subsidiaries, unless otherwise stated or the context so requires. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_2"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus supplement, as well as the information incorporated by reference in this prospectus or any
accompanying prospectus supplement, may include forward-looking statements made within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). Such
forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as &#147;will,&#148; &#147;may,&#148; &#147;could,&#148; &#147;likely,&#148;
&#147;ongoing,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;project,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;assume,&#148; &#147;target,&#148; &#147;forecast,&#148;
&#147;guidance,&#148; &#147;goal,&#148; &#147;objective,&#148; &#147;aim,&#148; and other words and terms of similar meaning, or by using future dates in connection with any discussion of, among other things, our anticipated operating and financial
performance, business plans and prospects, <FONT STYLE="white-space:nowrap">in-line</FONT> products and product candidates, including anticipated regulatory submissions, data read-outs, approvals, performance, timing of exclusivity and potential
benefits of Pfizer&#146;s products and product candidates, strategic reviews, capital allocation, business-development plans, manufacturing and product supply and plans relating to share repurchases and dividends. In particular, these include
statements relating to future actions, business plans and prospects, our acquisitions and other business development activities, the disposition of the Hospira Infusion Systems net assets, prospective products or product approvals, future
performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, plans relating to share repurchases and dividends, government
regulation and financial results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A list and description of risks, uncertainties and other matters can be found in our Annual
Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2017, including in the sections thereof captioned &#147;Forward-Looking Information and Factors That May Affect Future Results&#148; and
&#147;Item&nbsp;1A. Risk Factors,&#148; in our subsequent Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> and in this prospectus and any
accompanying prospectus supplement, in each case including in the section thereof captioned &#147;Risk Factors.&#148; You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any
such list to be a complete set of all potential risks or uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any forward-looking statement will be
realized, although we believe we have been prudent in our plans and assumptions. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties
materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements, and you
are cautioned not to put undue reliance on forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We undertake no obligation to publicly update forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects in our <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> reports and our other filings with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that
extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world&#146;s best-known consumer healthcare
products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support
and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products, and, to a much lesser extent, from alliance agreements, under which we <FONT STYLE="white-space:nowrap">co-promote</FONT>
products discovered or developed by other companies or us. The majority of our revenues come from the manufacture and sale of biopharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was incorporated under the laws of the State of Delaware on June&nbsp;2, 1942. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 235&nbsp;East 42nd Street, New York, NY 10017, and our telephone number is <FONT
STYLE="white-space:nowrap">(212)&nbsp;733-2323.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should consider carefully the information under the headings &#147;Risk Factors&#148; in our Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2017, in any applicable prospectus supplement and any risk factors set forth in our other filings with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d)
of the Exchange Act, including our Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and our Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> before making an investment decision. Each of the risks
described in these documents could materially and adversely affect our business, financial condition, results of operations and prospects, and could result in a partial or complete loss of your investment. See &#147;Where You Can Find More
Information.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_5"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated ratio of &#147;earnings&#148; to &#147;fixed charges&#148; for each of the years ended December 31, 2013 through 2017 is set
forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of computing the ratio of earnings to fixed charges, &#147;earnings&#148; consists of income from continuing
operations before provision for taxes on income and before income or loss from equity-method investments, plus fixed charges, distributed income of equity-method investments and amortization of capitalized interest, and less capitalized interest.
&#147;Fixed charges&#148; consists of interest expense (which includes amortization of debt premium, discount and other debt costs), preferred stock dividends, <FONT STYLE="white-space:nowrap">one-third</FONT> of rental expense, which we believe to
be a conservative estimate of an interest factor in our leases, which are not material, and capitalized interest. The ratio was calculated by dividing the sum of the earnings (as defined above) by the sum of the fixed charges (as defined above).
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratio of earnings to fixed charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement indicates otherwise, we intend to use net proceeds from the sale of the securities for general
corporate purposes, including working capital, capital expenditures, payment of dividends, share repurchases, acquisitions and the refinancing of existing debt. We may use funds that are not immediately needed for these purposes to temporarily
invest in short-term marketable securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless set forth in an accompanying prospectus supplement, we will not receive any proceeds
in the event that securities are sold by a selling security holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer debt securities in one or more series, which may be senior debt securities or subordinated debt securities and which may be
convertible into another security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description briefly sets forth certain general terms and provisions of the debt
securities. The particular terms of the debt securities offered by any prospectus supplement and the extent, if any, to which the following general terms and provisions may apply to the debt securities, will be described in an accompanying
prospectus supplement. Unless otherwise specified in an accompanying prospectus supplement, our debt securities will be issued in one or more series under an indenture to be entered into between us and The Bank of New York Mellon, as trustee, or
such other trustee named therein. A form of the indenture is attached as an exhibit to the registration statement of which this prospectus forms a part. The terms of the debt securities will include those set forth in the indenture and those made a
part of the indenture by the Trust Indenture Act of 1939 (TIA). You should read the summary below, any accompanying prospectus supplement and the provisions of the indenture in their entirety before investing in our debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate principal amount of debt securities that may be issued under the indenture is unlimited. The prospectus supplement relating to
any series of debt securities that we may offer will contain the specific terms of the debt securities. These terms may include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and aggregate principal amount of the debt securities and any limit on the aggregate principal amount
of such series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable subordination provisions for any subordinated debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date(s) or method for determining same; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate(s) or the method for determining same; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which interest will accrue or the method for determining dates on which interest will accrue and
dates on which interest will be payable and whether interest will be payable in cash, additional securities or some combination thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities are convertible or exchangeable into other securities and any related terms and
conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption or early repayment provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorized denominations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the principal amount, the principal amount of debt securities payable upon acceleration;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">place(s) where payment of principal and interest may be made, where debt securities may be presented and where
notices or demands upon the company may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form or forms of the debt securities of the series including such legends as may be required by applicable
law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in whole or in part in the form of one or more global securities and
the date as of which the securities are dated if other than the date of original issuance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities are secured and the terms of such security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of discount or premium, if any, with which the debt securities will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any covenants applicable to the particular debt securities being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additions or changes in the defaults and events of default applicable to the particular debt securities being
issued; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the guarantors of each series, if any, and the extent of the guarantees (including provisions relating to
seniority, subordination and release of the guarantees), if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency, currencies or currency units in which the purchase price for, the principal of and any premium and
any interest on, the debt securities will be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the time period within which, the manner in which and the terms and conditions upon which we or the holders of
the debt securities can select the payment currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our obligation or right to redeem, purchase or repay debt securities under a sinking fund, amortization or
analogous provision; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restriction or conditions on the transferability of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions granting special rights to holders of the debt securities upon occurrence of specified events;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or changes relating to compensation or reimbursement of the trustee of the series of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions relating to the modification of the indenture both with and without the consent of holders of debt
securities issued under the indenture and the execution of supplemental indentures for such series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities (which terms shall not be inconsistent with the provisions of the TIA, but
may modify, amend, supplement or delete any of the terms of the indenture with respect to such series of debt securities). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities in one or more series with the same or various maturities, at par or a premium or with original issue
discount. Unless we inform you otherwise in a prospectus supplement, we may issue additional debt securities of a particular series without the consent of the holders of the debt securities of such series or any other series outstanding at the time
of issuance. Any such additional debt securities, together with all other outstanding debt securities of that series, will constitute a single series of securities under the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in an accompanying prospectus supplement any other special considerations for any debt securities we sell that are
denominated in a currency or currency unit other than U.S. dollars. In addition, debt securities may be issued where the amount of principal and/or interest payable is determined by reference to one or more currency exchange rates, commodity prices,
equity indices or other factors. Holders of such securities may receive a principal amount or a payment of interest that is greater than or less than the amount of principal or interest otherwise payable on such dates, depending upon the value of
the applicable currencies, commodities, equity indices or other factors. Information as to the methods for determining the amount of principal or interest, if any, payable on any date, and the currencies, commodities, equity indices or other factors
to which the amount payable on such date is linked will be described in an accompanying prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">United States federal
income tax consequences and special considerations, if any, applicable to any such series will be described in an accompanying prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in an accompanying prospectus supplement, the debt securities will be issued in fully registered form without
coupons and in denominations of $2,000 and any integral multiple of $1,000 in excess thereof. Subject to the limitations provided in the indenture and in an accompanying prospectus supplement, debt securities that are issued in registered form may
be transferred or exchanged at the designated corporate trust office of the trustee, without the payment of any service charge, other than any tax or other governmental charge payable in connection therewith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed not to consolidate with or merge into any other person or convey or transfer our properties and assets as an entirety or
substantially as an entirety to any other person, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the successor expressly assumes, by a supplemental indenture, the due and punctual payment of the principal of
and any premium and/or any interest on all the debt securities and the performance and observance of all of the covenants and conditions of the indenture that we would otherwise have to perform; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we deliver to the trustee an officer&#146;s certificate and an opinion of counsel, each stating that the
consolidation, merger, conveyance or transfer and the supplemental indenture comply with the indenture. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successor
will assume all our obligations for payment under the securities and our obligations under the indenture as if it were an original party to the indenture. After assuming such obligations, the successor will have all our rights and powers under the
indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the indenture, we and the applicable trustee may supplement the indenture for certain purposes which would not adversely affect the
interests of the holders of debt securities of a series in any material respect without the consent of those holders. Under the indenture, the rights of the holders may be modified through a supplemental indenture if the holders of at least a
majority in aggregate principal amount of the outstanding debt securities of all series affected by the modification (voting as one class) consent to it. No modification of the maturity date, principal or interest payment terms or premium payable on
redemption, no modification of the currency for payment, no impairment of the right to sue for the enforcement of payment at the maturity of the debt security, no modification of any conversion rights, no modification reducing the percentage
required for any such supplemental indenture or the percentage required for the waiver of compliance with certain provisions of the indenture or certain defaults, and no modification of the foregoing provisions or any other provisions relating to
the waiver of past defaults or the waiver of certain covenants, is effective against any holder without its consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the following will constitute an event of default under the indenture with respect to debt securities of any series: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to make the principal or any premium payment on any debt security of such series when due;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to make any sinking fund payment for 60&nbsp;days after payment was due by the terms of any debt security
of such series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to pay interest on any debt security of such series for 60&nbsp;days after payment was due;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to perform any other covenant in the indenture and this failure continues for 90 days after we receive
written notice of it; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or a court, take certain actions relating to the bankruptcy, insolvency or reorganization of our company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The supplemental indenture or the form of security for a particular series of debt securities may include additional
events of default or changes to the events of default described above. The events of default applicable to a particular series of debt securities will be discussed in the prospectus supplement relating to such series. A default under our other
indebtedness will not be a default under the indenture for the debt securities covered by this prospectus, and a default under one series of debt securities will not necessarily be a default under another
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
series. The trustee may withhold notice to the holders of debt securities of any default (except for defaults that involve our failure to pay principal or interest) if it considers such
withholding of notice to be in the best interests of the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to outstanding debt securities of
any series occurs and is continuing, then the trustee or the holders of at least 33% in principal amount of outstanding debt securities of that series may declare, in a written notice, the principal amount (or, if any of the securities of that
series are original issue discount securities, such portion of the principal amount of such securities as specified in the terms thereof) plus accrued and unpaid interest on all debt securities of that series to be immediately due and payable. At
any time after a declaration of acceleration with respect to debt securities of any series has been made and before a judgment or decree for the payment of money due has been obtained by the trustee, the event of default giving rise to such
declaration of acceleration shall, without further act, be deemed to have been rescinded and annulled, if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have paid or deposited with the trustee or paying agent a sum sufficient to pay overdue interest and overdue
principal other than the accelerated interest and principal; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have cured or the holders have waived all events of default, other than the
<FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated principal and interest with respect to debt securities of that series, as provided in the indenture. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular provisions
relating to acceleration of a portion of the principal amount of the discount securities upon the occurrence of an event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a
default in the performance or breach of the indenture shall have occurred and be continuing, the holders of not less than a majority in principal amount of the outstanding securities of all series affected thereby, by notice to the trustee, may
waive any past event of default or its consequences under the indenture. However, an event of default cannot be waived without the consent of the holders of each outstanding security of the series affected with respect to any series of securities in
the following two circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a failure to pay the principal of, and premium, if any, or interest on any security or in the payment of any
sinking fund installment or analogous obligation; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covenant or provision that cannot be modified or amended without the consent of each holder of outstanding
securities of that series. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee is not obligated to exercise any of its rights or powers under the indenture at
the request, order or direction of any holders, unless the holders offer the trustee security or indemnity reasonably satisfactory to the trustee. Holders of a majority in principal amount outstanding of any series of debt securities may, subject to
certain limitations, direct the time, method and place of conducting any proceeding or any remedy available to the trustee, or exercising any power conferred upon the trustee, for such applicable series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to deliver an annual officer&#146;s certificate to the trustee stating whether we are in default in the performance and
observance of any of the terms, provisions and conditions of the indenture, and, if we are in default, specifying all such defaults and the nature and status thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Transfer and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
will pay principal, interest and any premium on fully registered securities at the place or places designated by us for such purposes. We will make payment to the persons in whose names the debt securities are registered on the close of business on
the record date for such interest. Any other payments will be made as set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders may transfer or exchange fully registered securities at any office or agency
maintained by us for such purposes, without the payment of any service charge except for any tax or governmental charge we are required to pay in connection with a transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon surrender for registration of transfer of any security of any series in accordance with the terms of the indenture, we shall execute, and
the trustee shall authenticate and deliver or make available for delivery, in the name of the designated transferee or transferees, one or more new securities of the same series, of any authorized denominations and of like tenor and aggregate
principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the securities of any series are to be redeemed, we are not required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register, transfer or exchange securities of any series during a period beginning at the opening of business
15&nbsp;days before the day we transmit a notice of redemption of securities of the series selected for redemption and ending at the close of business on the day of the transmission; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register, transfer or exchange any security so selected for redemption in whole or in part, except the unredeemed
portion of any security being redeemed in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we inform you otherwise in an accompanying prospectus supplement, the debt securities of a series may be issued in whole or in part in
the form of one or more global securities that will be deposited with, or on behalf of, a depositary identified in an accompanying prospectus supplement. Unless and until a global security is exchanged in whole or in part for the individual debt
securities, a global security may not be transferred except as a whole by the depositary for such global security to a nominee of such depositary or by a nominee of such depositary to such depositary or another nominee of such depositary or by such
depositary or any such nominee to a successor of such depositary or a nominee of such successor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we use the term defeasance, we mean discharge from some or all of our obligations under the indenture. Subject to certain additional
conditions, if we irrevocably deposit with the trustee sufficient cash or government securities to pay the principal, interest, any premium and any other sums due to the stated maturity date or a redemption date of the debt securities of a
particular series, then at our option: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will be discharged from our obligations with respect to the debt securities of such series; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will no longer be under any obligation to comply with certain restrictive covenants under the indenture, and
certain events of default will no longer apply to us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To exercise our defeasance option, we must deliver to the trustee
an officer&#146;s certificate and an opinion of counsel, each stating that all conditions precedent related to the defeasance have been complied with. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concerning the Trustee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee, The
Bank of New York Mellon, has provided banking and investment services to us in the past and may do so in the future as a part of its regular business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities shall be construed in accordance with and governed by the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_8"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of
certain terms of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by reference to, our restated certificate of incorporation, as amended (the Certificate of Incorporation), our <FONT
STYLE="white-space:nowrap">by-laws,</FONT> as amended (the <FONT STYLE="white-space:nowrap">By-Laws),</FONT> and the applicable provisions of the Delaware General Corporation Law (the DGCL). For more information on how you can obtain the Certificate
of Incorporation and the <FONT STYLE="white-space:nowrap">By-Laws,</FONT> see &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Certificate of Incorporation, we are authorized to issue up to 12&nbsp;billion shares of common stock, par value $0.05 per share. The
common stock is not redeemable, does not have any conversion rights and is not subject to call. Holders of shares of common stock have no preemptive rights to maintain their percentage of ownership in future offerings or sales of our stock. Holders
of shares of common stock have one vote per share in all elections of Directors and on all other matters submitted to vote of our stockholders. The holders of common stock are entitled to receive dividends, if any, as and when may be declared from
time to time by our Board of Directors out of funds legally available therefor. Upon liquidation, dissolution or winding up of our affairs, the holders of common stock will be entitled to participate equally and ratably, in proportion to the number
of shares held, in our net assets available for distribution to holders of common stock. The shares of common stock currently outstanding are fully paid and nonassessable. As of February&nbsp;20, 2018, there were 5,952,864,751&nbsp;shares of common
stock issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to any common stock being offered will include specific terms relating
to the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Certificate of Incorporation, we are authorized to issue up to 27&nbsp;million shares of preferred stock, without par value, of which
7,500&nbsp;shares of preferred stock have been designated Series A convertible perpetual preferred stock. The preferred stock may be issued in one or more series, and the Board of Directors of Pfizer is expressly authorized (i)&nbsp;to fix the
descriptions, powers, preferences, rights, qualifications, limitations, and restrictions with respect to any series of preferred stock and (ii)&nbsp;to specify the number of shares of any series of preferred stock. As of February&nbsp;20, 2018,
there were 517.05&nbsp;shares of preferred stock issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to any preferred stock being
offered will include specific terms relating to the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series&nbsp;A Convertible Perpetual Preferred Stock</I>. Our
Series&nbsp;A convertible perpetual preferred stock is held by an Employee Stock Ownership Plan (Preferred ESOP) Trust and provides dividends in an amount not to exceed 6.25% of the stated value, which are paid quarterly. The stated value is $40,300
per share, and the Series A convertible perpetual preferred stock ranks senior to our common stock and junior to all other preferred stock, unless designated as ranking senior or on a parity with the new preferred stock as to dividends and
liquidation rights. Each share is convertible, at the holder&#146;s option, at a conversion rate initially equivalent to 2,574.8685&nbsp;shares of our common stock for each preferred share converted, subject to adjustment. Each share of
Series&nbsp;A convertible perpetual preferred stock is entitled to a number of votes equal to the number of shares of common stock into which such convertible perpetual preferred stock could be converted on the record date for determining the
stockholders entitled to vote in any matter submitted to the stockholders to vote. The holders of Series&nbsp;A convertible perpetual preferred stock are entitled to vote on all matters submitted to a vote of the stockholders, voting together with
the holders of common stock as one class. The conversion option is indexed to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our common stock and requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the Series&nbsp;A convertible perpetual preferred stock at any
time or upon termination of the Preferred ESOP, at our option, in cash, in shares of common stock, or a combination of both at a price of $40,300 per share, plus any accrued and unpaid dividends to the redemption date. We will also redeem the
Series&nbsp;A convertible perpetual preferred stock in cash, or at our election, in shares of common stock, or a combination of any shares of common stock to be valued at their fair market value, at a price of $40,300 per share, upon certification
of the holder to us of certain events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of the Certificate of Incorporation, <FONT STYLE="white-space:nowrap">By-laws</FONT> and
Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT></I>. Various provisions contained in
the Certificate of Incorporation and the <FONT STYLE="white-space:nowrap">By-laws</FONT> could delay or discourage some transactions involving an actual or potential change in control of us or a change in our management and may limit the ability of
our stockholders to remove current management or approve transactions that our stockholders may deem to be in their best interests. Among other things, these provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the right of stockholders to call special meetings of stockholders to holders of at least 10% of the total
number of shares of stock entitled to vote on the matter to be brought before the proposed special meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our Board of Directors to establish one or more series of preferred stock without stockholder approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize the Board to issue dividends in the form of stock purchase or similar rights, including rights that
would have the effect of making an attempt to acquire us more costly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant to the Board of Directors, and not to the stockholders, the sole power to set the number of Directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action required or permitted to be taken by our stockholders must be effected at a duly called
annual or special meeting of stockholders and may not be effected by any consent in writing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to the rights of the holders of any one or more series of preferred stock then outstanding, allow our
Directors, and not our stockholders, to fill vacancies on our Board of Directors, including vacancies resulting from the removal of one or more Directors or an increase in the number of Directors constituting the whole Board of Directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware Law</I>. We are a Delaware corporation and consequently are also subject to certain anti-takeover
provisions of the DGCL. Subject to certain exceptions, Section&nbsp;203 of the DGCL prevents a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with any &#147;interested stockholder&#148; for three years
following the date that the person became an interested stockholder, unless (a)&nbsp;the interested stockholder attained such status with the approval of the corporation&#146;s board of directors, (b)&nbsp;upon consummation of the transaction that
resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, exclusive of shares owned by directors who are
also officers and by certain employee stock plans or (c)&nbsp;at or subsequent to such time, the business combination is approved by the board of directors and authorized by the affirmative vote at a stockholders&#146; meeting, and not by written
consent, of at least 66&nbsp;2/3% of the outstanding voting stock which is not owned by the interested stockholder. A &#147;business combination&#148; includes, among other things, a merger or consolidation involving the corporation and the
&#147;interested stockholder&#148; and the sale of more than 10% of the corporation&#146;s assets. In general, an &#147;interested stockholder&#148; is any entity or person beneficially owning 15% or more of the corporation&#146;s outstanding voting
stock, and any entity or person affiliated with or controlling or controlled by such entity or person. Section&nbsp;203 makes it more difficult for an interested stockholder to effect various business combinations with a corporation for a three-year
period. This statute could prohibit or delay mergers or other takeover or change in control attempts not approved in advance by our Board of Directors, and, as a result, could discourage attempts to acquire us, which could depress the market price
of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_9"></A>DESCRIPTION OF OTHER SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth, in the applicable prospectus supplement, a description of any warrants, depositary shares, purchase contracts, purchase
units or guarantees that may be offered pursuant to this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_10"></A>SELLING SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling securityholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our
securities in various private transactions. Such selling securityholders may be parties to registration rights agreements with us, or we otherwise may have agreed or will agree to register their securities for resale. The initial purchasers of our
securities, as well as their transferees, pledgees, donees or successors, all of whom we refer to as &#147;selling securityholders,&#148; may from time to time offer and sell the securities pursuant to this prospectus and any applicable prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will set forth the name of each selling securityholder and the number of and type of
securities beneficially owned by such selling securityholder that are covered by such prospectus supplement. The applicable prospectus supplement also will disclose whether any of the selling securityholders have held any position or office with,
have been employed by or otherwise have had a material relationship with us during the three years prior to the date of the prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and any selling securityholder may sell the securities offered by this prospectus from time to time in one or more transactions, including
without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through underwriters, brokers or dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on any national exchange on which the securities offered by this prospectus are listed or any automatic quotation
system through which the securities may be quoted; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to one or more purchasers; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of these methods. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we, or any selling securityholder, may enter into derivative or hedging transactions with third parties, or sell securities not
covered by this prospectus to third parties in privately negotiated transactions. In connection with such a transaction, the third parties may sell securities covered by and pursuant to this prospectus and an applicable prospectus supplement. If so,
the third party may use securities borrowed from us or others to settle such sales and may use securities received from us to close out any related short positions. We may also loan or pledge securities covered by this prospectus and an applicable
prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and any selling securityholder may sell the securities offered by this prospectus at: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will identify the specific plan of distribution, including any underwriters, dealers, agents or direct purchasers, and their compensation
in a prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Margaret&nbsp;M. Madden, our Senior Vice President and Corporate Secretary, Chief Governance Counsel, will pass upon the validity of the
securities for us. Ms.&nbsp;Madden beneficially owns, or has the right to acquire under our employee benefit plans, an aggregate of less than 1% of the outstanding shares of our common stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated balance sheets of Pfizer Inc. and Subsidiary Companies as of December&nbsp;31, 2017 and 2016 and the related consolidated
statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December&nbsp;31, 2017, and management&#146;s assessment of the effectiveness of internal control over financial reporting as of
December&nbsp;31, 2017, have been incorporated by reference herein in reliance upon the reports of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in auditing
and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc617367_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports,
statements or other information on file at the SEC&#146;s public reference room at 100&nbsp;F Street,&nbsp;N.E., Washington, D.C., 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the public reference room. The SEC filings are also available to the public from commercial document retrieval services. These filings are also available at
the Internet website maintained by the SEC at http://www.sec.gov. The filings are also available on our website at http://www.pfizer.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS INCORPORATES DOCUMENTS BY REFERENCE WHICH ARE NOT PRESENTED IN OR DELIVERED WITH THIS PROSPECTUS. YOU SHOULD RELY ONLY ON
THE INFORMATION CONTAINED IN THIS PROSPECTUS AND IN THE DOCUMENTS THAT WE HAVE INCORPORATED BY REFERENCE IN THIS PROSPECTUS. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION THAT IS DIFFERENT FROM OR IN ADDITION TO THE INFORMATION
CONTAINED IN THIS DOCUMENT AND INCORPORATED BY REFERENCE IN THIS PROSPECTUS. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate information into this prospectus by
reference, which means that we disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, except to the extent
superseded by information contained in this prospectus or by information contained in documents filed with the SEC after the date of this prospectus. This prospectus incorporates by reference the documents set forth below that have been previously
filed with the SEC. These documents contain important information about us and our financial condition. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pfizer&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended
December&nbsp;31, 2017 filed on February&nbsp;22, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pfizer&#146;s Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed on February&nbsp;23,
2018; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of Pfizer&#146;s common stock set forth in Pfizer&#146;s Registration Statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-A</FONT> filed on December&nbsp;6, 1997. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any
future filings made with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus and the date all of the securities offered by this prospectus are sold or the offering is otherwise
terminated, with the exception of any information furnished under Item&nbsp;2.02 and Item&nbsp;7.01 of <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> which is not deemed filed and which is not incorporated by reference in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this prospectus. Any such filings shall be deemed to be incorporated by reference and to be a part of this prospectus from the respective dates of filing of those documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide without charge upon written or oral request to each person, including any beneficial owner, to whom a prospectus is delivered,
a copy of any and all of the documents which are incorporated by reference in this prospectus but not delivered with this prospectus (other than exhibits unless such exhibits are specifically incorporated by reference in such documents). You may
request a copy of these documents by writing or telephoning us at: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Senior Vice President and Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pfizer Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 East 42nd Street
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(212) <FONT
STYLE="white-space:nowrap">733-2323</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The information contained in our website does not constitute a part of this prospectus.
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g617367g24t53.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g617367g24t53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g617367g24t53.jpg
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M 0$! 0$! 0$! 0$! ?_  !$( $< >0,!$0 "$0$#$0'_Q  =   " @,! 0$
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M"=<TID'RM+&;G8Q-HXDQH7&1$0Q3!@II6IB"8($E\=X!;9U[]-WJ+J\W\>S
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M107U53$,[^3JP6(0.M:.Q4:P""$>+Q:B=KF8G255>EATL$DFG.$9A2;7B ;
MV*95;%H)F/#F$;'2<QY:1L+S,S.7.JN95]NOYU],+M9!6J4ZF17M;F@F4\DK
M(5*;1B=YJ@*4586,QTUP6N-HGP8',OU9H^0VC[;3.$:OL,)7,TJXLXO+O(!+
M=T%=6V =O+2X] %7AK*A]@"/"1;G*,]*V,D9E4DQS20H'RV]/\Z/U17U+E,Z
MG)_@R7EBZM6HRO!N<EE<;-PV.9T]I33(*ZNY$ND#*QTJD&DSGGZS0YGZ NZ#
MT]I&U@9SLTUY_(W\DF[VZM2TBZRCC%HK)ED6;-=0-NV.S,5!:H:?78AM=(TS
M^ZK_ //Y)_?^/T_DG5F.*,+':(B/K]X_?^OC05?JJ_GUV!'O/ZOO]_KQZHC:
M(CC75?JOYKU]_7]'W_L\?MX[0CWG]7W_ +.-9Z]FN5?X+USQV1Y\<:'2X]''
MD]?G^77:$>/T\=H1X_3Q(^E]N93HC;.![>PPEX^0X%DE?>"QMF?!%9"P2>U;
M49KX_OK6Y!42G4MI$B+[M>>3'_O=^F34NGZ.JL!EM/Y((.IE:CJIS(P1)9,;
MU[2XGQWJE@%6D3^:U03].)AH?5F4T+JG ZNPS"#(8+)(OJ&#)8V5 71;HN(=
MY^&R%0GTK41$]5>PP?KQ<Y_UD/&#^U1?_I8O_P!'6;W^!_6O\P#_ 'D_\O&R
MW^,5RR_UJW_<_P#VXD?EOR0!X]:_:0 \<C/LK4JMPVNF1LC!Y(61_'Y";"Y'
M)(#2L(@5D+FN:98D B.;\,\J6!IT#HYNK<K(-@PQ5#H=D7#O$D)3/:J+*-MF
MV9 MRB8E:0:R)ZX 2DO-3F&C06"@TRMF<RG=KXBN6Q0N0&._D'!YW13@PV&8
MF&V&(5,=N6F"$:">^VGL.DJ"+ RTR3/LLK:R:R+DD*,)LL@M(19#299$5SW>
MZ2LTKWJC6L:Y55K&_*TUH*N#Q-FP"P33Q5!SA2N!6L$U$$<* 1]HZ0Z1B/,S
MM'F9\TBHV+NIL_3J&]EG(YS*5ZQV&E+6LL7[(*EK"G>2V)O64S,;1'F8B.'N
M<R\N"U/Q=RX.L5H2VE75:XH1T<C4^'N$CK2Q6+V[K[6+C6[VHUJJ[V>W9&]U
M;5_EUCV9[6]!CMV=A[\Q:/;?YZ^[EG/Z;QUXWF?SO??;BZO-[+HTMRURJT3"
M?B:U73]$-]ODM]-=JXW_ ).-7;*/?\CVVWF$S\.<,M]G<C-<BU\$\E?B5]7Y
MWD!L;7+!75F*&06L"DR-1?!+&U'KZB%O='.F.8J-2-LDD=B^8F1KX32&78XA
M%N0JNQ=-1;03GWED@NV,[;]E!ML%.VT"J?,SL,U"Y28NYJ;F%I]5<#*OBKR,
MW?<._17K8MH6@[DQ'RQ8M!7JA'CJ-\>.F"(6@>I'807&L]9ZA EB?EVW=OXG
MC^/!KV=.D,4DHYEDR+]]T(AUK3!R^/C_ -YL17HWRZ"?)M15\UFM0M$HQ^GM
M/9"Y;9Y@>HA$UIDO:"-2++!WW_S$[1,[<6-]1UE=G36FM)(,)R^KM78K'XY,
M_,?2)$MUB!CYI!3[5-)R.VWQ,;S$;SP3NZ,6H&:!R;6+,^Q_4E1>82[6E5EN
M1R!,K:4$ZI6D2!D1UO0PE%/I(RX!8&68LJ.19V*J0.:L)TU>MSJNCFYQ-S4%
MBKDHS3\?2%O>LM4_XGKDE5[9+7%F5F92ED;?).W5$\$?76+QP\O<MIC\8L;H
MVGD,&6F*F9RAH&K118J31Z!%]W' UTT1<M*QMI/JCN#,PN8X2A4^CSC^Q6&R
MX9S*PK*HJ^2&.PDQG @,B8!*2V1X[#9*K:Y"#23MCE?"V?VW2^V][$<V-4;9
MIWJ+M87M#D.6^2HDT9E47<NVG+1#I@Y4-C #UB,R,%([P.\1.TSYH4GT38_5
MHV3P7/3 Y84$ 63Q.G*^4BL3H(EBXJ>LF0HF")RON2,GL9#$P/@%\HX#8]C?
M,-.*=IR,Q6I#KL,CRO,-IY)C@6,U6-&%4TES7X^VDL\Z9#9%F#EXVD4G[2 R
M^%Y).P.1M:YI93H\VK=SEU^/J-&WWL=DIQ^.P5.ZRZ^ZM=B*SK<VD8OJ2M9K
MN]4?!-CJJP,L&7;KKQDO3;C,1SNCD_;YGXBK7J8(,QF]793%(Q-/%/=1*]6Q
ML4+>H8"T^PMV+Z"_"M<^C(&P4'%68<3='Z.6MLLM1Z+&.>VK<CNS?>42FH<0
MH+BU*0:"0F?X:OK]R$%SI -#*1,L4+O:@BDE?XQL<Y(+;]1>9HH.W>Y59VG5
M7T]RS;R%JN@),X .MSM.@L>LR$!ZBCJ,H&-YF(X,V-]$VE\M<51Q7J%TGE+S
M^YV*6/PN/N6W=M9-9*J];6[7,[:@-A] 3T+ C+81F8'GFSZ:M'PPU?79U><B
MP<QR'(K\:@Q3!H-;.Q\Z]>U$)N[!+!^?W,@E;15R),84VJ+C4TNIK9%'?:0S
MLF/++G39YD9MV*JZ.;CJE.HRWD,H69BVNK$_)65V1Q-:&.M.^1:Y>LNTNPZ.
MN$$,CWGGZ7Z')'2M;/W^92,WDLED58[#X!>F)QUC(%$=V]8^(G45XDU<?6CK
M<Z*C@^(=3JE*RMK.//CCZ3VWMOX.S;6W,RQWCEJ>2M^W(;[-Q?B<A)H&Q?$?
M;[Z JRH *.AE@198[+)L@J)GCNBL!ZXJNG@*EXUES]T]I[)S@-/8ZWK+/0[X
M8ZV,9T4PMR71\(-L$6VV[0EL,II4[ 042DG@X26/;RR](NL=88$=7ZPS6.Y:
MZ1*K\>%_.*[N1=C^B&_A$L>VSCZ]#'FO<@LY3(4V$OIL+JMK&MIRYD?I XSG
M>K,AV-Q)Y28EOZ?&'6(Y5 -55L(UM:5(C#RJ*NR2AR:\&!R"864=];66M;",
M=\:#+):A!DQE.CM/U#7L7G*F&U_H:_I,+O9,+1N?+*Z'LE06G4K=*J;:@L$X
M<]#B-7;:(UVL"0B;W_1SBL[I;(ZFY0\U<1S"9BYM*;CU5:@*MVZB8>VA7R=#
M*7E5\B:35-:K;K I_?0P[B$,%LB=P)]/.^YQ1;*/@V-#K&EUW)C07VF3B$N6
MI>6F0MN)G@#0,R3&VBK5B549!DKIR7?]8A,2%J/5_4\YJ\W:G+$L,DL.6;LY
M<;C>P&0&A\*BI-<8<9S3N=SOL>0+&!#_ #+)DIVB.!7R"].]_GF&I;"]1AIB
MEITL8GXIF'/+Q?M9&+AE74 Y+&PKX1-06.*6,G^,HB C>2XGZN]'/+3-[W6M
M;#>6+X[K>GL:O'0=IY1CL-!89_F9=,!=6F)ZOP(G,)R<O)QQEB-7W5FS(0@!
M;1AU=$A-C6F@Q15WJ+QZM+5LRG2]ZWF;"7VVX.E<*VG$XY=AM9&0SF5#'B&/
M&X26-K(FFQIH[;BE:7J:1'J>CG+-UU=TU8UQB\?IJC8JXY.JLGC0Q]C4&9;2
MKW;6*TO@69=C,NS'1977NVAR*4*MP^L$-LUGH =/4%]/"]X.$X%8Q[!%V3A>
MP7W(5?;+C[L7MZBZHXP"":VSJ_M>\&F@*$L(R*ZQ$L$69PYT)0 2P#2&RWE+
MS>K<SEY5!8D\-DL0-9C41;B[7L5K,M ')=\/6,36Q4@Y)JV&#40-9U&*X+S]
M]/=WD@S!6 U O4F&S\W$5[4T)QERI<HC7-M:S6BW=4P&JL"RO84^.N5O!J$]
MM9.'_P#T5-\_V?N?_*=_3J4_C[I7^<UOVJX@O^"K7O\ J^Y_ZO[^&G<T-ZS[
M8Y$9[8,+=-08I:$X+BT*2>4$=1C!1 $Y0[?/]RXMTLKE'JQ'^!\<;ONPQM:#
MN6^EPP.D,6HE0-N^@,I>*1CKFQ= &BLIV_[/7[-;;JVW41?G3Q9_G%K^=5<P
M<^X;$%0Q-IN#Q@242 U,8UE<W+WG;IN6QLW-]H+IL",^!B(E;TV\67/N2]/9
MS0K+7:]QZ[S$E9&(L*E^U%C]0SR\4[3QV-Y%8CM\O)5KGO3NV-W3#SDO#BM&
M6$A/2[+W*V.#:9ZNWN5NQ,1O/RDFJ23G;:(=$>)F.);Z<Z/XP<R*EB9AE?3^
M/NYAT>)#N] X^H,_+X,;%X+"XWWWKS,;P,\,SYO;DXJ8V3B>MN1U+F>5*Z!N
M>55%B4ID$<372V5 ,=92@9/C4ROD]NW'$C?/(Q&-+<BL>K54+\L].Z[N!?S&
MCK..HQU3BK%J^*CDI@4VC4D74KH[1U5S9,!$S,KB=QWXL?SLUMRKQ+L5IOF+
M3S.3(EQG*E'$D\!").S06^P=?)XTY(NBVM0D9#TPV8V*8W#$7U+N..D<<.HN
M.''JTK/BE1TA&2&56/M*)B8Y@Y=P4 ?F%Y>H.CG)#"=;P3)&][(B1O-W1'/D
MMK'4MQ=K6.K4OD/$!36^X2P*8DEUU.5CJU3K\=1+KD'5M,@>T<!#_&AY:Z(Q
MUBCRZY?VD2SR1Y%U2A#&C$PMMQM>QF+MV%[STA8N*.!F1!B^J9XB'B!LG8O,
MWG=BF?[).BLXM=4%]FC*D$=XF/X[75425=!74P3Y)W"PCY1D558+,3.18'3#
MR3%%%2HLT<BYA83$<N.5M[%X=1(+,VZF,E[BAMNXY\_$6W66P(=1%1J6$](
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MBXN-^@1M$?@C/BM7RNYBY_O#E=9;^I,A/KF81F@A6DF)V?%B&/8;>-.PTD0
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MU5UN%4]6\]6X3OO._OQR,CE7O\U55^:KW[JO?^/X]U^J_P#'IS ?K^S[_?\
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C3'V*K55J2N/'GI"-^.AZ\G#AQG2X7&=+A<9TN%QG2X7'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g617367g94r49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g617367g94r49.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1JP4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' (%  UP9FEZ
M97)?,F-?4$U3,CA"24T$)0      $#4S,"TB$B\69[>R")&HW*(X0DE-!#H
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ /      0 " \     !  (X0DE-!"8       X
M/X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _0
M !( -0    $ +0    8       $X0DE- _<      !P  /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      S4    &              "T   !
M+          !                          $              2P   "T
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   "T
M     %)G:'1L;VYG   !+     9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG    M     !29VAT;&]N9P
M 2P    #=7)L5$585     $       !N=6QL5$585     $       !-<V=E
M5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(
M5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N
M=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N
M96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R
M5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/
M=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M
M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M      P    "/_         X0DE-!!$       $! #A"24T$%       !
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M,]ZP^E,'5_K8+ZV%E)O=ED'D,K_FM_\ *?;Z.])3_]+6^N^4;NLMQY]F+4T
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M@  > T2VC=N&CAPX:'_.;[DZ22EBT%VYWN<.'.]Q_P YTI$ B")'@4B0 2=
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      7Y-30 J    "  , 0   P    $"!    0$  P
M  $!+    0(  P    ,   "> 08  P    $  @   1(  P    $  0   14
M P    $  P   1H !0    $   "D 1L !0    $   "L 2@  P    $  @
M 3$  @   !X   "T 3(  @   !0   #2AVD !     $   #H   !(  (  @
M"  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$X.C Y.C Q(# X.C(S.C,Q      20   '    !# R,C&@ 0 #
M ?__  "@ @ $     0   2R@ P $     0   +0         !@$#  ,    !
M  8   $:  4    !   !;@$;  4    !   !=@$H  ,    !  (   (!  0
M   !   !?@("  0    !              !(     0   $@    !.$))30/]
M       (          #_X0& 34T *@    @ # $   ,    ! @0   $!  ,
M   ! 2P   $"  ,    #    G@$&  ,    !  (   $2  ,    !      $5
M  ,    !  ,   $:  4    !    I $;  4    !    K $H  ,    !  (
M  $Q  (    >    M $R  (    4    TH=I  0    !    Z    2  "  (
M  @   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q.#HP.3HP,2 P.#HR,SHS,0     $D   !P    0P,C(QH $  P
M  '__P  H ( !     $   $LH , !     $   "T          8! P #
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ .@!@ P$1  (1 0,1 ?_$ !T   $$ P$!              D !@<(
M 04*! /_Q  W$   !@$"!0,# @4"!P     ! @,$!08'"!$ $A,A,0D4014B
M419A%R,D<8$RD4)2H;'!X?#_Q  4 0$                     _\0 %!$!
M                     /_:  P# 0 "$0,1 #\ [^. 7 +@*\9FU6Z?\ IJ
M$R?DJ!A9<J/73J[)12<MJY# (I&+7(=-[*((KB'(D[>MVK$3=C.B  B "URA
MZT<*W,LSPWB!])B!C$2G,BRB48CN', '+7*ZJ_763,( (=2Q,E.4=C)D-VX"
MC-U]4_6);E5/IMSKU":*;E]E3:A#$ "C_P KVS)6:43. #L)TWZ8[["4"FX"
MODQK(U6S9S'>ZALN)F,83F+%7B=@DP$1\%2@W<<B4O?_ $D3*4/ !L' -E/4
MSJ/1.51'/^:TU";B50N4[R0X>0$2B$[V[;AV'N&X#Y$. D&O:Z-7E8434C<_
MY#<BGL)2V"53MB0[#O\ >C:FTRDI\;@<AMPWWW 1X"X>,?6%U UE5JVR36*7
MDV+(8@.7:316G698FX<YB/HCKU_F*7<0(%8#F-L!E  >8 +[IQ]0'3[J0<,X
M"%FW%*OSO9-&BW8&T=(R*X$ QTZ[)(KKQ%@$1Z@I-&CM.9.DDHNK$()%$P!=
M_@%P$=9-RM1\15\EAN\L+%%V\1BH.)8M7,M9+5/.]P85VJ5V.3<2UAGI!0.1
MK&QK9=80YEENBV2673 %^J'61KCRF>3K^(\&YOPUCO=9(9)GCFY%R',L]C%%
M61GV\0HG6TU"\J@,JRHF[0-S)JV!^@<4P +$NC+H2CY.>2DD)GW*IY(DPFZ3
ME/>',)EC/2/0*[!R<YN947/\TQQYCB)A[@2;1GHPIU]QO<]3FH=W+1F"Z"QF
MY!M"1*RT?*7D]9;G<S!BOB=-RE!H+)J0R!8IPVDY>>ZS!J_C_8JBY"SFBG$.
MG?6HUS,G8=-^/<>TVI.8&.ICFE6B_)7^/4F4YE0%9B6?6A\TF%VK5BV53?K1
M39BY>BNFK&/$@4!( ZYDI$9C7+62L>PLS^HHBDWFSU:.F]D>>29P<P[CD'*_
MM_Z<7(D;E*[]O_3BY!7H;)"0. C7\?\ 4.W_ -^XF#P'CL' +_L/[[_[B'?O
MN(;>?]N R ?C;SX']_@?.X;?N'SVWX#Z)J*(J)K(J&2724*HDHF8Q54U""!D
MU$SD$IR'*<I3%.40,4_W ("' ='GICZXYS+Z:N!<N2QY6_0,4M(4FV/U0-(V
M^!C2D]]#S*ZB@J2%EA6Y@=HR&QG,Q"H.G,ASOXQX_D0(OJ,U!4C33B^9R9=U
MC*I-!*PK\ V533D[59'2:IXZ"C>IN!5%^BJX>.C$.G'1K9X_5(H1OTC@##1K
M>\EZTM>L!E')\B+YEC6$LEXCJ^WZI:W5F3<A(6NPD"T.<Y6_MIJP1TD=VN96
M0DUHQ5V^<KK 4Q0W_J(ZU,V4+5+)5##V39^G0N.J_6HN2CHM1FO$R5F>-SV1
M^\>QS]J]8/U$FDQ&Q:R3QNJD48XZ1T]N?<+0^HMCN+R1HOHV7+I6HZ.SK'LL
M2J(+,&2;63<V"ZFAHZS4H##S.5XTKJ6?OVL<NJL+5U$(J)&+NYZP/G6%B^[X
M[T#5;3SARD6>[2KAO0:'+-:9 R4V]+'Q!/U+9["[1BVRRB*4S.PA4WBZB:::
MJ\Z<FP=3E  +-\2ZN\,15AMC2AY[Q="%C#)6FPL8:[TZ/^CB<I3)3<FV3CTC
M,.JH4H$>JBB"AR[;&-W!OQ6E[4E88N.G8?!&7)>(FF+26BY9C0K.\92D=(-T
MW;)^S=I1QTG35XW63<MW"9S)K(JE43.)3 (@W[M@?->-H<EAR!B?(-)@3O48
MY.8M%2FX*-/(.2+*MV1'DDS;H'=K)-EU4D"G%0Y$5C@42IG$ ]^/M.N=\K1R
MDOCG$M\N$,F=1$9F'KT@O#BLF8 502E#HIL%W">X=1!%P=9,1^\@>. 9\GC3
M(<-=D,;RU'M49?W,@RBFU->04DVLSJ1DE")1S1I#JMB/G*TB=5,&(((* [ZJ
M8H&4(<H\ ZGVGS.T59X*ER6'LE1]MM"3EQ7:T[IT\WFYELQ,0KYU'1RS$KET
MU9"H07CE-,4&H& RZB9-QX"9-.E9R9@W61I\B;A5K'1+2?*M 8*15ABWD0^5
M@K?8&U8D%DD7*29G#%[&2$FU!TB*C942N$@4$R:@%"8?5$SW)9:U'S5':.U!
MIF&E5Z;$LB*C[=>S)BF:XRZR6XD!Y]6)]!*8>8 9P;<R8)G<+@8+U^C9065>
MQKF7-4OR-$Y>=:U-J_<@)"-H.FQ?UZ9=D/L >U6=3R!5S%[=2(,4?N2X"OTO
M*^FNCFJR9^OV<,AYRFYJZ2MZ+0XK&T_!UXS][)*R+&-?%G8>+^JQL4)D&S9F
MK.L6;E%JDWD4W#4RS10)'::L9+U =6^G[&5=JKVL88H-\+E)Y'RZC=U-V%[1
M(Y[-,I:S),CKQ\>R2713A6,.U=/T2K3"Z[N1=G6:H,0WGJ@:GLQTO...,1X4
MOUGJ3U*J-9":;561.Q7E9ZX3:S&&CGO2^Y15LSBVRS5,P@!2S(F /YN_ 35Z
MHUTDL8Z-Z?BYU.NYJQWJ5IE/FIA^Y.O*3<?3H]*?L$VZ<J""BSA_.0\)[Y4^
MW5&44*8 !3;@(.T'P^I&;J['/^?M05\H>FVA1R;R#A)2S.8EG;(V!33;MCN"
M#TO8T1ET",R$1_JK"LD6,C4A:*"NH'LA+XR]4#58RJ[QL^::7\%LG5Q"NN>J
MT=W^5]VC$1SR=*B<BK$)I9PK[9B"@K,:TQDVH*-I*7=G0"8]1=1U06[,\3"Q
M60H'2=I%Q@O7T&UH:9!K%.//,HQ-JZE7S2*A)5.03,0XK0L#!SOT>!;-6";]
M=(5W"R!P;,%D''NL3U):#/X[!&<I.G3',])O;:5J9-M:9TCURP8&CU5"D67B
M8F8L[%>(<K$3]RY82CMH51BJW<+A"_J#ZW;CC35!&5K#CMM"OL:-*HC?II%N
MB9_;W*3P+:G0GT@<JBZ-.;LI1(LK'QRC,\E)R3XLB9<T5&"W#[X,R58O40UO
M8URN\H#6C4G3U5TIA^T2EE;"=641?/W==2<39HJ'34>/;,\1D&+ &")$(N!D
ME 467,<Q@$/G]I),,[YI93)5"RK;+&0TI'K;F4,\);9;W!CG, "?G4YE.KW!
M0IP.',4P#P!>8G5+@+$GIM*X>HV2HB2S!,8R>1<A7(]C.I2+>QY-DCJ6\AWZ
MT2WCQ<5J.L4FC[DCPQ#?2$BM3JAT>8 4_O\ &W;SMXV_'[=O[=Q'@#=^BYC<
MSRZY?RRY0_D0%=BJ%%+'+N4SVQ/RSDQTA$-@5:M*_$E4$!YP3D>40Y5.X5SD
MLJXZOOJ:/\J9-M#&"QI6LON7Q9U^D]=QXQ>*FIX^G@DW8-7JZR,U)5F&,"9$
M#)B#]557[!4'@+ :N<]Z<-3VK33_  D[DM@MISHL(]E[E8RM+"W8/)5\[?24
MG7BH%BR2^\LC7JM"K.V[0@MV\HZ5;N4U4><H64U.95T+:FJO5J)*:N'6/Z'5
MC$53J-'KL@TB))RU13:Q1Y!-Y2W)A;P;0#H1,>@*+%J*RBW0.L1N= *H:<,Y
M:5M%FIF0B*'DBQY&PQD/'D1&V7(KZ*,96MW)"=?.V6T8SA8J0<032- J4D=M
M'NW97,FFLB19)FHF(;+.N"M ]NRG;<Z3>M.*&IW"<D;E,XYIS:/M=R4DI=PI
M)2K"(?,'\B_BDG\@LL9JVDZ><T<#CH*.0(D"Q =N@;/6C3#-GU#7I2V)XLB+
MM<(^(QS4;4G.S%AC*%"-%'Q%73N,932!2R<K** #=62=N4?IB:"SIWT2/' "
MY+7\EZPM1-H/1X%W.V[*%VL-G]N '(R@8F4EUG7O9AZ)5$8N!@&;ELU6>.!$
MJ::3=J@#EXX:H+!U4:4=,U3TL8ICJ! *$E)QVH68N]J,B**]FLJR*:3AR1(Q
MCF:Q3%(A&$-'@<0;,D057,M(.GSIR :_5;TC3E;O#[4M28I=_2[<+(N2$621
MU1J]J332CTIYTDDF((05B129E7>G_EM[#UP=*D-,,2" 7]P_&X!MMO\ C</\
M? _C\=_ !D!_Q^0#;_/@0VVV\_\ L1#I5T9%3TR^FS:<ON" A,S4'D+*R150
M AEI)5 ]:HS3F, ;IR1(2OJ(;[EYY0QB[\_<.:LYSJ&.<YS'.<YCG.<>8ZAS
M#N)SF'?F,8PB8PB(B([C\<!@.X[;AMX -_C\]O/;]P_ _/ 8\"/-\COO_;X^
M?&^P[;B'<.X< M@W[ &P?/DOCP(_W^1']MOC@%\;]OR(B._?;MY#X_R/D-^
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
